

cobas[®] CT/NG

Qualitative nucleic acid test for use on the cobas[®] 6800/8800 Systems

For in vitro diagnostic use

cobas[®] CT/NG

P/N: 07460066190

cobas[®] CT/NG Positive Control Kit

P/N: 07460082190

**cobas[®] 6800/8800 Buffer Negative
Control Kit**

P/N: 07002238190

Table of contents

Intended use	5
Summary and explanation of the test.....	5
Reagents and materials.....	8
cobas® CT/NG reagents and controls.....	8
cobas omni reagents for sample preparation.....	9
Reagent storage and handling requirements.....	10
Additional materials required	11
Instrumentation and software required	12
Precautions and handling requirements	12
Warnings and precautions	12
Reagent handling	13
Good laboratory practice.....	13
Specimen collection, transport, and storage	14
Specimen collection	14
Specimen transport	14
Specimen storage.....	14
Male and female urine specimens	14
Endocervical, vaginal, anorectal and oropharyngeal specimens.....	15
Cervical specimens in PreservCyt® Solution	16
Instructions for use.....	16
Procedural notes	16
Running cobas® CT/NG.....	17
Results	19
Quality control and validity of results.....	19
Interpretation of results	19
Procedural limitations.....	22

Performance evaluation..... 24

Key performance characteristics	24
Limit of Detection (LoD)	24
Precision.....	24
Analytical specificity/cross reactivity	26
Interference.....	27
Competitive inhibition.....	30
Whole system failure	30
Cross contamination	31
Clinical performance using clinical specimens.....	31
Clinical study - Prospective collection of urogenital specimens	33
Clinical study – Prospective collection of extra-genital specimens	36

Results..... 37

Urogenital specimens – Clinical study.....	37
Extragenital specimens – Clinical study	37
<i>Chlamydia trachomatis</i> : Urogenital specimens infection status summary	37
<i>Chlamydia trachomatis</i> : Extragenital specimens infection status summary	40
<i>Chlamydia trachomatis</i> : performance results	42
<i>Neisseria gonorrhoeae</i> : Urogenital specimens Infection Status summary	43
<i>Neisseria gonorrhoeae</i> : Extragenital specimens Infection Status summary	46
<i>Neisseria gonorrhoeae</i> : performance results	48
Expected values for urogenital specimens	50
Prevalence	50
Positive and negative predictive values for hypothetical prevalence rates.....	51
Expected values for extragenital specimens.....	52
Prevalence	52
Positive and negative predictive values for hypothetical prevalence rates.....	52
Cycle threshold frequency distribution	55

Additional information 58

Key assay features 58

Symbols..... 59

Technical support..... 60

Manufacturer and importer 60

Trademarks and patents 60

Copyright..... 60

References..... 61

Document revision..... 63

Intended use

cobas® CT/NG for use on the **cobas® 6800/8800 Systems** is an automated, qualitative in vitro diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of *Chlamydia trachomatis* (CT) and/or *Neisseria gonorrhoeae* (NG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens, clinician-collected vaginal swab specimens, endocervical swab specimens, oropharyngeal (throat) swab specimens, and anorectal swab specimens, all collected in **cobas® PCR Media** (Roche Molecular Systems, Inc.), and cervical specimens collected in PreservCyt® Solution. This test is intended as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals.

Summary and explanation of the test

Background

Infection with CT is the leading bacterial cause of sexually transmitted diseases worldwide, with approximately 89.1 million cases occurring annually.¹ *C. trachomatis* is the most frequently reported bacterial sexually transmitted disease (STD) in the United States^{1,2} and prevalence is highest in persons aged ≤ 24 years.³ In 2013, a total of 1,401,906 cases of *C. trachomatis* infection were reported to the CDC corresponding to a rate of 446.6 cases per 100,000 population.³ CT is a gram-negative, nonmotile, obligate intracellular bacterium with a unique biphasic lifecycle.¹ CT causes a variety of infections including urethritis, cervicitis, proctitis, conjunctivitis, endometritis, and salpingitis; if left untreated, the infection may ascend to the uterus, fallopian tubes, and ovaries causing pelvic inflammatory syndrome, ectopic pregnancy, and tubal factor infertility. Reiter's syndrome (urethritis, conjunctivitis, arthritis, and mucocutaneous lesions) has also been associated with genital CT infection.¹ Many infections remain asymptomatic, and high numbers of infected patients may not seek care.⁴ Patients often become re-infected if their sexual partners are not treated. Infants born to infected mothers can develop conjunctivitis, pharyngitis, and pneumonia. The predominant symptoms in men and women are increased discharge and dysuria; women may also present with irregular uterine bleeding.¹

The diagnosis of *C. trachomatis* urogenital infection in women is made by testing first-catch urine or collecting swab specimens from the endocervix or vagina. Diagnosis of *C. trachomatis* urethral infection in men can be made by testing a urethral swab or first-catch urine specimen. Nucleic acid amplification tests (NAATs) are the most sensitive tests for these specimens and therefore are recommended for detecting *C. trachomatis* infection.⁵ Anorectal and oropharyngeal *C. trachomatis* infection in persons engaging in receptive anal or oral intercourse can be diagnosed by testing at the anatomic site of exposure.

Annual screening for CT of all sexually active women aged < 25 years is recommended and screening of older women is recommended in the presence of increased risk for infection (e.g., those who have a new sex partner, more than one sex partner, a sex partner with concurrent partners, or a sex partner who has a sexually transmitted infection).⁶ Chlamydia screening programs have been demonstrated to reduce the rates of PID in women.^{7,8} Although the evidence to support routine screening for CT in sexually active young men is insufficient, due to the relative lack of feasibility, efficacy, and cost-effectiveness studies, the screening of sexually active young men should be considered in clinical settings with a high prevalence of chlamydia (e.g., adolescent clinics, correctional facilities, and STD clinics) or in populations with high burden of infection (e.g., MSM).^{2,6} The primary focus of chlamydia screening efforts among women should be to detect chlamydia, prevent complications, and test and treat their partners, whereas targeted chlamydia screening in men should only be considered when resources permit, prevalence is high, and such screening does not hinder chlamydia screening efforts in women.^{9,10} More frequent screening for some women (e.g., adolescents) or certain men (e.g., MSM) might be indicated.²

NG is the etiologic agent of gonorrhea. NG are cytochrome oxidase-positive, non-motile, non-spore forming gram-negative diplococci. In the United States, an estimated 820,000 new *N. gonorrhoeae* infections occur each year.¹¹ Gonorrhea is the second most commonly reported communicable disease.³ Clinical manifestations of NG infections are numerous.⁴ In men, acute urethritis presents itself after a 1-10 day incubation period with urethral discharge and dysuria. Only a small proportion of men remain asymptomatic without signs of urethritis.¹² Acute epididymitis is the most common complication, especially in young men. In women, the primary site of infection is the endocervix. There is a high prevalence of coalescence of symptoms with CT, *Trichomonas vaginalis*, and vaginosis; many women remain asymptomatic and therefore do not seek medical care. In symptomatic women increased discharge, dysuria, and intermenstrual bleeding may be observed.¹³ Pelvic inflammatory disease (PID) can occur in 10%-20% of women, combined with endometritis, salpingitis, tubo-ovarian abscess, pelvic peritonitis, and perihepatitis.¹⁴ PID can result in tubal scarring that can lead to infertility and ectopic pregnancy. Other gonococcal infected sites in men and women are the rectum, pharynx, conjunctiva, and to a lesser degree the disease presents itself as disseminated gonococcal infection. Infants from infected mothers can develop conjunctivitis.

Annual screening for *N. gonorrhoeae* infection is recommended for all sexually active women aged < 25 years and for older women at increased risk for infection (e.g., those who have a new sex partner, more than one sex partner, a sex partner with concurrent partners, or a sex partner who has an STI).⁶ Additional risk factors include inconsistent condom use among persons with multiple sex partners, previous or coexisting sexually transmitted infections, and exchanging sex for money or drugs.² In addition to urethral infections, the CDC also recommends the use of NAATs for routine annual screening for men who have sex with men (MSM) for anorectal or oral infection.⁵

Rationale for CT/NG testing

NAATs are the recommended method for CT and NG screening.¹⁵ For women, a vaginal swab is the recommended sample type and first catch urine is recommended for men. Alternative acceptable sample types for women include an endocervical swab when a pelvic examination is indicated or a first catch urine sample, but a urine sample may detect up to 10% fewer infections when compared with vaginal and endocervical swabs. In addition to urine for men, a urethral swab is also acceptable. In addition, the CDC recommends at least annual screening for CT from urethral or anorectal specimens and for NG from urethral, anorectal or oral specimens in MSM.²

cobas® CT/NG for use on the **cobas® 6800/8800 Systems** (referred to as **cobas® CT/NG** throughout the remainder of this document) is an automated, qualitative real-time PCR test designed to detect CT and NG DNA in urogenital, oropharyngeal and anorectal specimens from male and female patients and thus fulfills the medical need for a rapid, high throughput molecular screening test for use as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals.

Explanation of the test

cobas® CT/NG is a qualitative test performed on the **cobas® 6800 System** and **cobas® 8800 System**. **cobas® CT/NG** enables the detection of CT/NG DNA in endocervical, vaginal, oropharyngeal, anorectal, urine and cervical specimens of infected female patients and oropharyngeal, anorectal and urine specimens in male patients. Target-specific primers and two probes are used to detect but not discriminate between the CT cryptic plasmid and the *ompA* gene. Additionally, target-specific primers and two probes are used to detect but not discriminate between two conserved sequences in the NG DR-9 region. The DNA Internal Control, used to monitor the entire sample preparation and PCR amplification process, is introduced into each specimen during sample processing. In addition, the test utilizes a low titer positive and a negative control.

Principles of the procedure

cobas® CT/NG is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The **cobas**® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the **cobas**® 6800/8800 software which assigns test results for all tests as positive, negative or invalid. Results can be reviewed directly on the system screen, exported, or printed as a report.

Nucleic acid from patient samples, external controls and added internal control DNA (DNA-IC) molecules is simultaneously extracted. In summary, bacterial nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors are removed with subsequent wash steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.

Selective amplification of target nucleic acid from the sample is achieved by the use of target-specific forward and reverse primers which are selected from highly conserved plasmid and genomic regions of CT and NG. A region on the CT cryptic plasmid and the *ompA* gene (dual target) and two conserved sequences of the NG DR-9 region are amplified by **cobas**® CT/NG. Selective amplification of DNA IC is achieved by the use of sequence-specific forward and reverse primers which are selected to have no homology with either the CT or NG target regions. A thermostable DNA polymerase enzyme is used for PCR amplification. The target and DNA-IC sequences are amplified simultaneously utilizing a universal PCR amplification profile with predefined temperature steps and number of cycles. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythymidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme, which is included in the PCR master mix, during the first thermal cycling step.¹⁶ However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.

The **cobas**® CT/NG master mix contains two detection probes specific for the CT target sequences, two detection probes specific for the NG target sequences and one for the DNA-IC. The probes are labeled with target specific fluorescent reporter dyes allowing simultaneous detection of CT targets, NG targets and DNA-IC in three different target channels.^{17,18} When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by a quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage of the probe by the 5' to 3' exonuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye increases concomitantly. Real-time detection and discrimination of PCR products is accomplished by measuring the fluorescence of the released reporter dyes for the CT and NG targets and DNA-IC, respectively.

Reagents and materials

cobas® CT/NG reagents and controls

All unopened reagents and controls shall be stored as recommended in Table 1 to Table 4.

Table 1 cobas® CT/NG

cobas® CT/NG Store at 2-8°C 480 test cassette (P/N 07460066190)		
Kit components	Reagent ingredients	Quantity per kit 480 tests
Proteinase Solution (PASE)	Tris buffer, < 0.05% EDTA, Calcium chloride, Calcium acetate, 8% Proteinase EUH210: Safety data sheet available on request. EUH208: Contains Subtilisin. May produce an allergic reaction.	38 mL
DNA Internal Control (DNA-IC)	Tris buffer, < 0.05% EDTA, < 0.001% non-CT/NG related DNA construct containing primer and probe specific sequence regions, < 0.1% Sodium azide	38 mL
Elution Buffer (EB)	Tris buffer, 0.2% Methyl-4 hydroxybenzoate	38 mL
Master Mix Reagent 1 (MMX-R1)	Manganese acetate, Potassium hydroxide, < 0.1% Sodium azide	14.5 mL
CT/NG Master Mix Reagent 2 (CT/NG MMX-R2)	Tricine buffer, Potassium acetate, EDTA, Glycerol, < 18% Dimethyl sulfoxide, < 0.12% dATP, dCTP, dGTP, dUTPs, < 0.1% Tween 20, < 0.1% Sodium azide, < 0.1% Z05 DNA polymerase, < 0.10% AmpErase (uracil-N glycosylase) enzyme (microbial), < 0.01% Internal Control forward and reverse primers, < 0.01% Upstream and downstream CT/NG primers, < 0.01% Fluorescent-labeled oligonucleotide probes specific for CT, NG and the DNA Internal Control, < 0.01% Oligonucleotide aptamer	17.5 mL

Table 2 cobas® CT/NG Positive Control Kit

cobas® CT/NG Positive Control Kit Store at 2-8°C (P/N 07460082190)		
Kit components	Reagent ingredients	Quantity per kit
CT/NG Positive Control (CT/NG (+) C)	Tris buffer, < 0.05% Sodium azide, < 0.005% EDTA, < 0.003% Poly rA, < 0.01% Non-infectious plasmid DNA (microbial) containing <i>C. trachomatis</i> , < 0.01% Non-infectious plasmid DNA (microbial) containing <i>N. gonorrhoeae</i>	16 mL (16 x 1 mL)

Table 3 cobas® 6800/8800 Buffer Negative Control Kit

cobas® 6800/8800 Buffer Negative Control Kit Store at 2-8°C (P/N 07002238190)		
Kit components	Reagent ingredients	Quantity per kit
cobas® 6800/8800 Buffer Negative Control (BUF (-) C)	Tris buffer, < 0.1% sodium azide, EDTA, < 0.002% Poly rA RNA (synthetic)	16 mL (16 x 1 mL)

cobas omni reagents for sample preparation

Table 4 cobas omni reagents for sample preparation*

Reagents	Reagent ingredients	Quantity per kit	Safety symbol and warning**
cobas omni MGP Reagent (MGP) Store at 2–8°C (P/N 06997546190)	Magnetic glass particles, Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	480 tests	Not applicable
cobas omni Specimen Diluent (SPEC DIL) Store at 2–8°C (P/N 06997511190)	Tris buffer, 0.1% methyl-4 hydroxybenzoate, < 0.1% sodium azide	4 x 875 mL	Not applicable
cobas omni Lysis Reagent (LYS) Store at 2–8°C (P/N 06997538190)	42.56% (w/w) guanidine thiocyanate***, 5% (w/v) polydocanol***, 2% (w/v) dithiothreitol***, dihydro sodium citrate	4 x 875 mL	  DANGER H302 + H332: Harmful if swallowed or if inhaled. H314: Causes severe skin burns and eye damage. H412: Harmful to aquatic life with long lasting effects. EUH032: Contact with acids liberates very toxic gas. P261: Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray. P273: Avoid release to the environment. P280: Wear protective gloves/protective clothing/eye protection/face protection. P303 + P361 + P353: IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water. P304 + P340 + P310: IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/doctor. P305 + P351 + P338 + P310: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor. 593-84-0 Guanidinium thiocyanate 9002-92-0 Polidocanol 3483-12-3 (R*,R*)-1,4-dimercaptobutane-2,3-diol
cobas omni Wash Reagent (WASH) Store at 15–30°C (P/N 06997503190)	Sodium citrate dihydrate, 0.1% methyl-4 hydroxybenzoate	4.2L	Not applicable

* These reagents are not included in the cobas® CT/NG kit. See listing of additional materials required (Table 7).

** Product safety labeling primarily follows EU GHS guidance

*** Hazardous substance

Reagent storage and handling requirements

Reagents shall be stored and will be handled as specified in Table 5 and Table 6.

When reagents are not loaded on the cobas® 6800/8800 Systems, store them at the corresponding temperature specified in Table 5.

Table 5 Reagent storage (when reagent is not on the system)

Reagent	Storage temperature
cobas® CT/NG	2–8°C
cobas® CT/NG Positive Control Kit	2–8°C
cobas® Buffer Negative Control Kit	2–8°C
cobas omni Lysis Reagent	2–8°C
cobas omni MGP Reagent	2–8°C
cobas omni Specimen Diluent	2–8°C
cobas omni Wash Reagent	15–30°C

Reagents loaded onto the cobas® 6800/8800 Systems are stored at appropriate temperatures and their expiration is monitored by the system. The cobas® 6800/8800 Systems allow reagents to be used only if all of the conditions shown in Table 6 are met. The system automatically prevents use of expired reagents. Table 6 allows the user to understand the reagent handling conditions enforced by the cobas® 6800/8800 Systems.

Table 6 Reagent expiry conditions enforced by the cobas® 6800/8800 Systems

Reagent	Open-kit stability	Number of runs for which this kit can be used	On-board stability (cumulative time on board outside refrigerator)
cobas® CT/NG	90 days from first usage	Max 20 runs	Max 20 hours
cobas® CT/NG Positive Control Kit	Not applicable	Not applicable	Max 10 hours
cobas® Buffer Negative Control Kit	Not applicable	Not applicable	Max 10 hours
cobas omni Lysis Reagent	30 days from loading*	Not applicable	Not applicable
cobas omni MGP Reagent	30 days from loading*	Not applicable	Not applicable
cobas omni Specimen Diluent	30 days from loading*	Not applicable	Not applicable
cobas omni Wash Reagent	30 days from loading*	Not applicable	Not applicable

* Time is measured from the first time that reagent is loaded onto the cobas® 6800/8800 Systems.

Additional materials required

Table 7 Materials and consumables for use on **cobas®** 6800/8800 Systems

Material	P/N
cobas omni Processing Plate	05534917001
cobas omni Amplification Plate	05534941001
cobas omni Pipette Tips	05534925001
cobas omni Liquid Waste Container	07094388001
cobas omni Lysis Reagent	06997538190
cobas omni MGP Reagent	06997546190
cobas omni Specimen Diluent	06997511190
cobas omni Wash Reagent	06997503190
Solid Waste Bag	07435967001
Solid Waste Container	07094361001
cobas® PCR Media Secondary Tube Kit	07958048190
cobas® PCR Media Tube Replacement Cap Kit	07958056190
Replacement Caps for PreservCyt® Vials	08037230190
cobas® PCR Media Disposable Tube Stand (Optional)	07958064190
MPA RACK 16 MM LIGHT GREEN 7001-7050 ^{a,b}	03143449001
RD5 RACK – RD Standard rack 0001-0050 LR ^{a,b}	11902997001

^a MPA 16mm and RD5 racks are required to use **cobas®** CT/NG. Contact your local Roche representative for a detailed order list for sample racks, racks for clotted tips and rack trays accepted on the instruments.

^b MPA 16mm rack is the preferred rack. If RD5 racks are used, ensure sample tubes are filled with the recommended minimum sample input volume. Rationale: The tubes sit higher in an RD5 rack because of the rubber gasket at the bottom of each tube position. Because of this, it is possible that when using RD5 racks, the system could accept tubes that are below the minimum sample input volume and cause pipetting errors later in the run.

Table 8 Specimen collection kits used with **cobas®** CT/NG

Collection Kit	P/N
cobas® PCR Media Kit	06466281190
cobas® PCR Urine Sample Kit	05170486190
cobas® PCR Media Uni Swab Sample Kit	07958030190
cobas® PCR Media Dual Swab Sample Kit	07958021190
ThinPrep Pap Test Physician's Kit (500 vials & Broom-like collection devices)	Hologic: 70136-001
ThinPrep Pap Test Physician's Kit (500 vials & Cytobrush/spatula collection devices)	Hologic: 70136-002

Instrumentation and software required

The cobas® 6800/8800 software and cobas® CT/NG analysis packages (ASAPs) shall be installed on the instrument(s). The Instrument Gateway (IG) server will be provided with the system.

Table 9 Instrumentation

Equipment	P/N
cobas® 6800 System (Moveable Platform)	05524245001 and 06379672001
cobas® 6800 System (Fixed Platform)	05524245001 and 06379664001
cobas® 8800 System	05412722001
Sample Supply Module	06301037001
Instrument Gateway	06349595001

cobas® CT/NG accepts the primary tube used for all cobas® PCR CT/NG swab and urine specimen types. Refer to the cobas® 6800/8800 Systems User Guide for additional information for primary and secondary sample tubes accepted on the instruments.

Precautions and handling requirements

Warnings and precautions

As with any test procedure, good laboratory practice is essential to the proper performance of this assay. Due to the high sensitivity of this test, care should be taken to keep reagents and amplification mixtures free of contamination.

- For in vitro diagnostic use only.
- All patient samples should be handled as if infectious, using good laboratory procedures as outlined in Biosafety in Microbiological and Biomedical Laboratories and in the CLSI Document M29 -A4.^{19,20} Only personnel proficient in handling infectious materials and the use of cobas® CT/NG and cobas® 6800/8800 Systems should perform this procedure.
- All human-sourced materials should be considered potentially infectious and should be handled with universal precautions. If spillage occurs, immediately disinfect with a freshly prepared solution of 0.5% sodium hypochlorite in distilled or deionized water (dilute household bleach 1:10) or follow appropriate site procedures.
- Do not freeze any samples.
- Use only supplied or specified required consumables to ensure established test performance.
- Safety Data Sheets (SDS) are available on request from your local Roche representative.
- Closely follow procedures and guidelines provided to ensure that the test is performed correctly. Any deviation from the procedures and guidelines may affect established test performance.
- False positive results may occur if carryover of samples is not adequately controlled during sample handling and processing.
- cobas® PCR Media (from primary specimen tube) contains guanidine hydrochloride. **Do not allow direct contact between guanidine hydrochloride and sodium hypochlorite (bleach) or other highly reactive reagents such as acids or bases. These mixtures can release a noxious gas.** If liquid containing guanidine hydrochloride is spilled, clean with suitable laboratory detergent and water. If the spilled liquid contains potentially infectious agents, **FIRST** clean the affected area with laboratory detergent and water, and then with 0.5% sodium hypochlorite.
- Inform your local competent authority about any serious incidents which may occur when using this assay.

Reagent handling

- Handle all reagents, controls, and samples according to good laboratory practice in order to prevent carryover of samples, reagents, or controls.
- Before use, visually inspect each reagent cassette, diluent, lysis reagent, and wash reagent to ensure that there are no signs of leakage. If there is any evidence of leakage, do not use that material for testing.
- **cobas omni** Lysis Reagent contains guanidine thiocyanate, a potentially hazardous chemical. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur.
- Expended control kits contain pierced vials with residual reagent; special care should be taken during disposal to avoid spills and contact.
- **cobas**® CT/NG kit, **cobas**® CT/NG Positive Control kit, **cobas**® Buffer Negative Control kit, **cobas omni** MGP Reagent, and **cobas omni** Specimen Diluent contain sodium azide as a preservative. Avoid contact of reagents with the skin, eyes, or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, burns can occur. If these reagents are spilled, dilute with water before wiping dry.
- Do not allow **cobas omni** Lysis Reagent, which contains guanidine thiocyanate, to contact sodium hypochlorite (bleach) solution. This mixture can produce a highly toxic gas.
- Dispose of all materials that have come in contact with samples and reagents in accordance with country, state, and local regulations.

Good laboratory practice

- Do not pipette by mouth.
- Do not eat, drink, or smoke in designated work areas.
- Wear laboratory gloves, laboratory coats, and eye protection when handling samples and reagents. Avoid contaminating gloves when handling samples and controls. Gloves must be changed between handling samples and **cobas**® CT/NG kit, **cobas**® CT/NG Positive Control kit, **cobas**® 6800/8800 Buffer Negative Control kit, and **cobas omni** reagents to prevent contamination.
- Wash hands thoroughly after handling samples and reagents, and after removing the gloves.
- Thoroughly clean and disinfect all laboratory work surfaces with a freshly prepared solution of 0.5% sodium hypochlorite in distilled or deionized water (dilute household bleach 1:10). Follow by wiping the surface with 70% ethanol.
- If spills occur on the **cobas**® 6800/8800 Systems, follow the instructions in the **cobas**® 6800/8800 Systems User Guide to properly clean and decontaminate the surface of instrument(s).

Specimen collection, transport, and storage

Note: Handle all samples and controls as if they are capable of transmitting infectious agents.

Specimen collection

Endocervical swab specimens collected with the **cobas**® PCR Media Dual Swab Sample Kit, vaginal swab specimens, anorectal swab specimens and oropharyngeal swab specimens collected with either the **cobas**® PCR Media Uni Swab Sample Kit or **cobas**® PCR Media Dual Swab Sample Kit, male and female urine collected with the **cobas**® PCR Urine Sample Kit and cervical specimens collected in PreservCyt® Solution have been validated for use with **cobas**® CT/NG (see Table 8 for a list of all collection kits). Follow the instructions for collecting all swab and urine specimens in their respective collection kit IFU. Follow the manufacturer's instructions for collecting cervical specimens into PreservCyt® Solution.

Specimen transport

All specimen types listed in Specimen Collection section above can be transported at 2-30°C. Transportation of CT/NG specimens in **cobas**® PCR Media and PreservCyt® Solution must comply with country, federal, state and local regulations for the transport of etiologic agents.²¹

Specimen storage

Table 10 Summary of acceptable specimen storage conditions prior to testing with **cobas**® CT/NG

Specimen Type	2-30°C
Samples in cobas ® PCR Media	12 months
PreservCyt® in collection device or PreservCyt® samples aliquoted to secondary tubes	12 months 31 days

Note: PreservCyt® and **cobas**® PCR Media specimens should not be frozen.

Male and female urine specimens

- Use only the **cobas**® PCR Urine Sample Kit or the **cobas**® PCR Media Kit to collect urine specimens for **cobas**® CT/NG. **cobas**® CT/NG has not been validated for use with other urine collection devices or media types. Using **cobas**® CT/NG with other urine collection devices or other media types may lead to false negative, false positive, and/or invalid results.
- To avoid cross contamination of processed specimens, additional caps for **cobas**® PCR Media tubes in an alternate color (neutral; see **Additional materials required**) should be used to recap specimens after processing.
- Untested urine specimens must show the top of the liquid level between the two black lines on the **cobas**® PCR Media tube label window. If the liquid level is above or below these lines, the specimen has not been collected properly and cannot be used for testing.
- If additional testing is required, ensure that there is at least 1.2 mL of specimen remaining the in **cobas**® PCR Media tube.

Endocervical, vaginal, anorectal and oropharyngeal specimens

- The presence of mucus in endocervical and cervical specimens may cause processing delays due to clotting. Mucus free specimens are required for optimal test performance. Use the large woven polyester swab in the **cobas**® PCR Media Dual Swab Sample Kit or an equivalent device to remove cervical secretions and discharge before obtaining the endocervical or cervical specimen.
- Use only the flocked swab in the **cobas**® PCR Media Dual Swab Sample Kit to collect endocervical specimens. Use only the woven polyester swab in either the **cobas**® PCR Media Uni Swab Sample Kit or the **cobas**® PCR Media Dual Swab Sample Kit to collect vaginal, anorectal, and oropharyngeal swab specimens. **cobas**® CT/NG has not been validated for use with other swab collection devices or media types. Using **cobas**® CT/NG with other swab collection devices or media types may lead to false negative, false positive, and/or invalid results.
- To avoid cross contamination of processed specimens, additional caps for **cobas**® PCR Media tubes in an alternate color (neutral; see **Additional materials required**) should be used to recap specimens after processing.
- All swab specimens containing a single swab in the **cobas**® PCR Media tube can be directly processed on the **cobas**® 6800/8800 Systems. If desired, the swab may be removed before the specimen tube is loaded onto the instrument, however utmost care must be exercised to avoid cross contamination.
- A properly collected swab specimen should have a single swab with the shaft broken at the score line. Swab shafts which are broken above the score line will appear longer than normal and may also be bent over to fit into the **cobas**® PCR Media tube. This can create an obstruction to the pipetting system which may cause the loss of sample, test results and/or mechanical damage to the instrument. In the event that a swab specimen has an improperly broken shaft, remove the swab prior to sample processing on the **cobas**® 6800/8800 Systems. Use caution when disposing of specimen swabs; avoid splashing or touching swabs to other surfaces during disposal to prevent contamination.
- Incoming primary swab specimen tubes with no swabs or with two swabs have not been collected according to the instructions in their respective collective kit IFU and should not be tested.
- Occasionally, incoming swab specimens contain excessive mucus which may induce a pipetting error (e.g., clot or other obstruction) on the **cobas**® 6800/8800 Systems. Prior to retesting of specimens that exhibited clots during initial processing, remove and discard the swab, then re-cap and vortex these specimens for 30 seconds to disperse the excess mucus.
- Swab specimens can be assayed twice on the **cobas**® 6800/8800 Systems while the swab is in the collection tube. If additional testing is required, or if the first test fails due to specimen pipetting error (e.g., clot or other obstruction), the swab must be removed prior to testing and the remaining fluid must have a minimum volume of 1.0 mL.

Cervical specimens in PreservCyt® Solution

- cobas® CT/NG is validated for use with cervical specimens collected in PreservCyt® Solution. cobas® CT/NG has not been validated for use with cervical specimens obtained in other media types. Using cobas® CT/NG with other media types may lead to false negative, false positive, and/or invalid results.
- Cervical specimens in PreservCyt® Solution should be aliquoted into secondary tubes as follows:
 1. Prepare a barcoded 13 mL round-bottom cobas® PCR Secondary tube for each PreservCyt® specimen to be tested.
 2. With clean gloved hands, **vortex** each PreservCyt® primary specimen vial for **10 seconds** immediately **prior** to transfer.
 3. Uncap a primary vial and transfer at least **1.0 mL** but no more than **4.0 mL** into the prepared barcoded secondary tube from step 1.
 - *Always use caution when transferring specimens from primary containers to secondary tubes.*
 - *Always use a new pipette tip for each specimen.*
 - *Always use pipettors with aerosol-barrier or positive-displacement tips to handle specimens.*
 - *To avoid cross contamination, additional caps for these tubes in an alternate color (neutral; see **Additional materials required**) should be used to recap these specimens after processing.*
 - *Transfer tube to a rack if testing is to be performed shortly after or cap the secondary tube if testing will be performed at a future time.*
 4. Re-cap the primary vial with a replacement cap before moving to the next specimen. Store the primary vial upright.
 5. Only racks of uncapped tubes may be loaded into the Sample Supply Module of the cobas® 6800/8800 Systems for CT/NG testing.
- Aliquots of the primary specimen must contain a minimum volume of 1.0 mL.

Instructions for use

Procedural notes

- Do not use cobas® CT/NG, cobas® CT/NG Positive Control Kit, cobas® Buffer Negative Control Kit, or cobas omni reagents after their expiry dates.
- Do not reuse consumables. They are for one-time use only.
- Ensure that specimen barcode labels on sample tubes are visible through the openings on the side of MPA sample racks. Refer to the cobas® 6800/8800 Systems User Guide for proper barcode specifications and additional information on loading sample tubes.
- Refer to the cobas® 6800/8800 Systems User Guide for proper maintenance of instruments.

Running cobas® CT/NG

cobas® CT/NG can be run with a minimum required sample volume of 1.0 mL for swab and PreservCyt® specimens, and 1.2 mL for urine specimens. The operation of the instrument is described in detail in the cobas® 6800/8800 Systems User Guide. Figure 1 below summarizes the procedure.

- Swab and urine specimens should be uncapped and loaded directly onto racks for processing on the cobas® 6800/8800 Systems.
- It is necessary to aliquot specimens collected in PreservCyt® Solution. Refer to the preparation instructions for cervical specimens found in section: “Cervical specimens in PreservCyt® Solution”.
- A single run can have any combination of specimens (Swab, Urine, and PreservCyt®) and each specimen can be tested with either the CT/NG, CT, or NG ASAPs.
- Specimens collected in cobas® PCR Media or PreservCyt® Solution should be processed using the sample type selection in the user interface (UI) of the cobas® CT/NG as described in Table 11.

Table 11 Sample type selection in the user interface of the cobas® CT/NG

Specimen		Collection kit type	Process as Sample Type
Female	Vaginal swab	cobas® PCR Media Uni or Dual Swab Sample Kit	Swab
	Endocervical swab	cobas® PCR Media Dual Swab Sample Kit	Swab
	Oropharyngeal swab	cobas® PCR Media Uni or Dual Swab Sample Kit	Swab
	Anorectal swab	cobas® PCR Media Uni or Dual Swab Sample Kit	Swab
	Urine	cobas® PCR Urine Sample Kit or cobas® PCR Media Kit	Urine
	Cervical swab	PreservCyt® Solution (ThinPrep)	PreservCyt®
Male	Oropharyngeal swab	cobas® PCR Media Uni or Dual Swab Sample Kit	Swab
	Anorectal swab	cobas® PCR Media Uni or Dual Swab Sample Kit	Swab
	Urine	cobas® PCR Urine Sample Kit or cobas® PCR Media Kit	Urine

Figure 1 cobas® CT/NG procedure

1	Log onto the system Press Start to prepare the system Order Tests • Choose “Swab” for ordering swab specimens collected in cobas® PCR Media • Choose “Urine” for ordering urine specimens collected in cobas® PCR Media • Choose “PreservCyt” for ordering PreservCyt® Solution specimens
2	Refill reagents and consumables as prompted by the system • Load test specific reagent cassette • Load control cassettes • Load pipette tips • Load processing plates • Load MGP Reagent • Load amplification plates • Refill Specimen Diluent • Refill Lysis Reagent • Refill Wash Reagent
3	Loading specimens onto the system • For each primary urine or swab in cobas® PCR Media ◦ Uncap tube ◦ Transfer tube directly to rack • For each primary PreservCyt® specimen vial: ◦ Vortex for 10 seconds ◦ Aliquot a minimum of 1 mL of PreservCyt® specimen into a 13 mL round-bottom secondary tube ◦ Transfer tube to rack • Load sample rack and clot tip racks into the sample supply module • Confirm samples have been accepted into the transfer module
4	Start run
5	Review and export results
6	Remove sample tubes. If needed, cap any sample tubes meeting the minimum volume requirements for future use. Clean up instrument • Unload empty control cassettes • Empty amplification plate drawer • Empty liquid waste • Empty solid waste

Results

cobas® CT/NG automatically detects and discriminates CT and/or NG DNA simultaneously for samples and controls, displaying individual target results for samples as well as validity and overall results for controls.

Quality control and validity of results

- One cobas® Buffer Negative Control [(-) Ctrl] and one CT/NG Positive Control [CT/NG (+) C] are processed with each batch of a requested result type.
- In the cobas® 6800/8800 software and/or report, check for flags and their associated results to ensure batch validity.
- All flags are described in the cobas® 6800/8800 Systems User Guide.
- The batch is valid if no flags appear for all controls. If the batch is invalid, repeat testing of the entire batch.

Validation of results is performed automatically by the cobas® 6800/8800 software based on negative and positive control performance.

Interpretation of results

Display examples cobas® CT/NG are shown in Figure 2, Figure 3, and Figure 4, respectively.

Figure 2 Example of cobas® CT/NG results display for the CT/NG result request

Test	Sample ID	Valid	Flags	Sample type	Overall result	Target 1	Target 2
CT/NG	C161420284084196207422	Yes		CT/NG (+) C	Valid	Valid	Valid
CT/NG	C161420284090419545972	Yes		(-) Ctrl	Valid	Valid	Valid
CT/NG 400 ul	CTNG_PC1	NA		PreservCyt®	NA	CT Positive	NG Positive
CT/NG 400 ul	CTNG_PC2	NA		PreservCyt®	NA	CT Negative	NG Positive
CT/NG 400 ul	CTNG_Swab1	NA		Swab	NA	CT Negative	NG Negative
CT/NG 400 ul	CTNG_Swab2	NA		Swab	NA	CT Positive	NG Positive
CT/NG 850 ul	CTNG_Urine1	NA		Urine	NA	CT Positive	NG Negative
CT/NG 850 ul	CTNG_Urine2	NA		Urine	NA	CT Negative	NG Negative
CT/NG 850 ul	CTNG_Urine3	NA	Y40T	Urine	NA	Invalid	Invalid

Figure 3 Example of cobas® CT results display for the CT/NG result request

Test	Sample ID	Valid	Flags	Sample type	Overall result	Target 1	Target 2
CT	C161420284084196207423	Yes		CT/NG (+) C	Valid	Valid	
CT	C161420284090419545973	Yes		(-) Ctrl	Valid	Valid	
CT 400 ul	CT_PC1	NA		PreservCyt®	NA	CT Positive	
CT 400 ul	CT_PC2	NA		PreservCyt®	NA	CT Positive	
CT 400 ul	CT_Swab1	NA		Swab	NA	CT Negative	
CT 400 ul	CT_Swab2	NA		Swab	NA	CT Positive	
CT 400 ul	CT_Swab3	NA	P02T	Swab	NA	Invalid	
CT 850 ul	CT_Urine1	NA		Urine	NA	CT Negative	
CT 850 ul	CT_Urine2	NA		Urine	NA	CT Positive	

Note: The Target 2 column is reserved for NG results.

Figure 4 Example of cobas® NG results display for the CT/NG result request

Test	Sample ID	Valid	Flags	Sample type	Overall result	Target 1	Target 2
NG	C161420284084196207424	Yes		CT/NG (+) C	Valid		Valid
NG	C161420284090419545974	Yes		(-) Ctrl	Valid		Valid
NG 400 ul	NG_PC1	NA		PreservCyt®	NA		NG Negative
NG 400 ul	NG_PC2	NA		PreservCyt®	NA		NG Positive
NG 400 ul	NG_PC3	NA	Y40T	PreservCyt®	NA		Invalid
NG 400 ul	NG_Swab1	NA		Swab	NA		NG Positive
NG 400 ul	NG_Swab2	NA		Swab	NA		NG Negative
NG 850 ul	NG_Urine1	NA		Urine	NA		NG Negative
NG 850 ul	NG_Urine2	NA		Urine	NA		NG Positive

Note: The Target 1 column is reserved for CT results.

For a valid batch, check each individual sample for flags in the **cobas**® 6800/8800 software and/or report. The result interpretation should be as follows:

- A valid batch may include both valid and invalid sample results.
- The “Valid” and “Overall Result” columns are not applicable (NA) to sample results for the **cobas**® CT/NG Test and are marked with “NA”. Values reported in these columns **do not** impact the validity of results reported within individual Target Result columns.
- Reported target results for individual samples are valid unless indicated as “Invalid” within the individual target result column.
- Invalid results for one or more target combinations are possible with the CT/NG result request and are reported out specifically for each channel. Refer to retesting instructions for the respective specimen type.
- Results of this test should only be interpreted in conjunction with information available from clinical evaluation of the patient and patient history.

Results and their corresponding interpretation for detecting CT and NG (Table 12), CT only (Table 13) and NG only (Table 14) are shown below.

Table 12 **cobas**® CT/NG results and interpretation for the CT/NG result request

Target 1	Target 2	Interpretation
CT Positive	NG Positive	All requested results were valid. Target signal detected for CT and NG DNA.
CT Positive	NG Negative	All requested results were valid. Target signal detected for CT DNA. No target signal detected for NG DNA.
CT Negative	NG Positive	All requested results were valid. No target signal detected for CT DNA. Target signal detected for NG DNA.
CT Negative	NG Negative	All requested results were valid. No target signal detected for CT or NG DNA.
CT Positive	Invalid	Not all requested results were valid. CT result is valid. Target signal detected for CT DNA. NG result is invalid. Original specimen should be re-tested to obtain valid NG results. If the result is still invalid, a new specimen should be obtained.
Invalid	NG Positive	Not all requested results were valid. CT result is invalid. Original specimen should be re-tested to obtain valid CT results. If the result is still invalid, a new specimen should be obtained. NG result is valid. Target signal detected for NG DNA.
CT Negative	Invalid	Not all requested results were valid. CT result is valid. No target signal detected for CT DNA. NG result is invalid. Original specimen should be re-tested to obtain valid NG results. If the result is still invalid, a new specimen should be obtained.
Invalid	NG Negative	Not all requested results were valid. CT result is invalid. Original specimen should be re-tested to obtain valid CT results. If the result is still invalid, a new specimen should be obtained. NG result is valid. No target signal detected for NG DNA.
Invalid	Invalid	Both CT and NG results are invalid. Original specimen should be re-tested to obtain valid CT and NG results. If the results are still invalid, a new specimen should be obtained.

Table 13 cobas® CT/NG results and interpretation for the CT result request

Target 1	Target 2	Interpretation
CT Positive	<Blank>	The requested result was valid. Target signal detected for CT DNA.
CT Negative	<Blank>	The requested result was valid. No target signal detected for CT DNA
Invalid	<Blank>	CT result is invalid. Original specimen should be re-tested to obtain valid CT results. If the result is still invalid, a new specimen should be obtained.

Table 14 cobas® CT/NG results and interpretation for the NG result request

Target 1	Target 2	Interpretation
<Blank>	NG Positive	The requested result was valid. Target signal detected for NG DNA.
<Blank>	NG Negative	The requested result was valid. No target signal detected for NG DNA
<Blank>	Invalid	NG result is invalid. Original specimen should be re-tested to obtain valid NG results. If the result is still invalid, a new specimen should be obtained.

Procedural limitations

- cobas® CT/NG has been evaluated only for use in combination with the cobas® CT/NG Positive Control Kit, cobas® Buffer Negative Control Kit, cobas omni MGP Reagent, cobas omni Lysis Reagent, cobas omni Specimen Diluent, and cobas omni Wash Reagent for use on the cobas® 6800/8800 Systems.
- Reliable results depend on proper sample collection, storage and handling procedures.
- Products containing carbomer(s), including vaginal lubricants, creams and gels may interfere with the test and should not be used during or prior to collecting urogenital specimens. See Interference results (Table 19) for further details.
- cobas® CT/NG has only been validated for use with male and female urine, clinician-instructed self-collected vaginal swab specimens, clinician-collected vaginal swab specimens, anorectal swab specimens, oropharyngeal swab specimens and endocervical swab specimens, all collected in cobas® PCR Media (Roche Molecular Systems, Inc.) and cervical specimens collected in PreservCyt® Solution. Assay performance has not been validated for use with other collection media and/or specimen types.
- Detection of *C. trachomatis* and *N. gonorrhoeae* is dependent on the number of organisms present in the specimen and may be affected by specimen collection methods, patient factors (i.e., age, history of STD, presence of symptoms), stage of infection and/or infecting *C. trachomatis* and *N. gonorrhoeae* strains.
- Though rare, mutations within the highly conserved regions of the cryptic plasmid or genomic DNA of *C. trachomatis* or the genomic DNA of *N. gonorrhoeae* covered by cobas® CT/NG primers and/or probes may result in failure to detect the presence of the bacterium.

- *N. gonorrhoeae* may occasionally exchange genetic material with commensal bacteria commonly found in the normal microflora of the mouth and throat. It is possible that this exchange may include isolated DNA sequences which could, on rare occasion, produce a positive signal with this assay.²²
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. Users should follow their own specific policies/procedures.
- **cobas® CT/NG** is not intended to replace other exams or tests for diagnosis of urogenital infection. Patients may have cervicitis, urethritis, urinary tract infections, or vaginal infections due to other causes or concurrent infections with other agents.
- **cobas® CT/NG** is not recommended for evaluation of suspected sexual abuse and for other medico-legal indications.
- **cobas® CT/NG** should not be used to determine therapeutic success as nucleic acids may be present after antimicrobial therapy.
- **cobas® CT/NG** for urine testing is recommended to be performed on first catch urine specimens (defined as the first 10 to 50 mL of the urine stream). The effects of other variables such as first-catch vs. mid-stream, post-douching, etc. have not been evaluated.
- The effects of other potential variables such as vaginal discharge, use of tampons, douching, etc. and specimen collection variables have not been evaluated.
- **cobas® CT/NG** has not been evaluated with patients who were currently being treated with antimicrobial agents active against CT or NG as well as patients with a history of hysterectomy.
- False negative or invalid results may occur due to polymerase inhibition. The CT/NG Internal Control is included in **cobas® CT/NG** to help identify the specimens containing substances that may interfere with nucleic acid isolation and PCR amplification.
- The addition of AmpErase enzyme into the **cobas® CT/NG** Master Mix reagent enables selective amplification of target DNA; however, good laboratory practices and careful adherence to the procedures specified in this Package Insert are necessary to avoid contamination of reagents.
- **cobas® CT/NG** has not been evaluated in patients younger than 14 years of age.

Performance evaluation

Key performance characteristics

Limit of Detection (LoD)

The *Chlamydia trachomatis* analytical sensitivity claim for the assay is 40 Elementary Bodies (EB) per mL for all serovars (A, B, Ba, C, D, E, F, G, H, I, J, K, L1, L2, L3) as well as for the Swedish variant nvCT, in all claimed specimen types. However, dilutions of some serovars below 40 EB/mL have tested positive using cobas® CT/NG for use on the cobas® 6800/8800 Systems.

The *N. gonorrhoeae* analytical sensitivity claim for the assay is 1.0 Colony Forming Units (CFU) per mL (45 gonorrhoeae strains tested) in all claimed specimen types. However, dilutions of gonorrhoeae strains below 1.0 CFU/mL have tested positive using cobas® CT/NG for use on the cobas® 6800/8800 Systems.

Precision

In-house precision was examined using a panel composed of CT and NG cultures diluted into a pool of negative endocervical swab specimen matrix collected in cobas® PCR Media, a pool of negative urine matrix plus cobas® PCR Media and a pool of negative cervical specimen matrix collected in PreservCyt® Solution. Endocervical swabs were intended to represent all swab samples collected in cobas® PCR Media (endocervical, vaginal, oropharyngeal, and anorectal). Four levels were tested using CT serovar D and NG strain 2948 (ATCC 19424) as the target organisms.

The precision panel was designed to include members with very low, low and medium concentrations of CT and NG (≤ 0.7 EB/mL and ≤ 0.07 CFU/mL, ≤ 4 EB/mL and ≤ 0.4 CFU/mL and ≤ 12 EB/mL and ≤ 1.2 CFU/mL) for each panel matrix. Testing was performed with three lots of cobas® CT/NG reagents and two instruments for a total of 24 runs. A description of the precision panels and the study performance hit rate is shown in Table 15. All negative panel members tested negative throughout the study. Analysis of standard deviation and percent coefficient of variation of the Ct values from valid tests performed on positive panel members (see Table 16 and Table 17) yielded overall CV (%) ranges from 1.62% to 4.05% for CT and from 1.17% to 3.55% for NG.

Table 15 Summary of within laboratory precision

Target Concentration		N Tested	N positive CT	N positive NG	Hit Rate		95% CI CT		95% CI NG	
CT	NG				CT	NG	LL	UL	LL	UL
Endocervical Swab in cobas [®] PCR Media										
Neg	Neg	72	0	0	0%	0%	0.0	5.0	0.0	5.0
0.7 EB/mL	0.07 CFU/mL	72	51	32	71%	44%	59	81	33	57
2 EB/mL	0.4 CFU/mL	72	69	68	96%	94%	88	99	86	98
6 EB/mL	1.2 CFU/mL	72	72	72	100%	100%	95	100	95	100
cobas [®] PCR Media with Urine										
Neg	Neg	72	0	0	0%	0%	0.0	5.0	0.0	5.0
0.3 EB/mL	0.05 CFU/mL	72	38	47	53%	65%	66	87	66	87
1 EB/mL	0.2 CFU/mL	72	72	69	100%	96%	92	100	95	100
3 EB/mL	0.6 CFU/mL	72	72	72	100%	100%	95	100	95	100
Cervical samples collected into PreservCyt [®] Solution										
Neg	Neg	72	0	0	0%	0%	0.0	5.0	0.0	5.0
0.7 EB/mL	0.07 CFU/mL	72	56	56	78%	78%	41	65	53	76
4 EB/mL	0.2 CFU/mL	72	71	72	99%	100%	95	100	88	99
12 EB/mL	0.6 CFU/mL	72	72	72	100%	100%	95	100	95	100

Table 16 Overall mean, standard deviations and coefficients of variation (%) for cycle threshold, CT panel members 2, 3, and 4

Hit Rate	Mean Ct	Between instrument		Between lot		Within run		Between run		Between day		Total	
		SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%
Endocervical Swab in cobas ® PCR Media													
71%	39.7	0.00	0.00	0.00	0.00	1.27	3.21	0.00	0.00	0.34	0.85	1.32	3.32
96%	38.5	0.00	0.00	0.04	0.10	1.14	2.96	0.00	0.00	0.48	1.25	1.24	3.22
100%	36.9	0.00	0.00	0.25	0.69	0.54	1.45	0.07	0.18	0.00	0.00	0.60	1.62
Cervical Samples collected into PreservCyt® Solution													
53%	38.3	0.60	1.57	0.52	1.37	1.12	2.92	0.00	0.00	0.00	0.00	1.37	3.58
100%	36.9	0.21	0.56	0.28	0.76	0.68	1.85	0.00	0.00	0.00	0.00	0.77	2.08
100%	35.6	0.00	0.00	0.20	0.56	0.52	1.46	0.09	0.24	0.02	0.05	0.56	1.59
cobas ® PCR Media with Urine													
78%	38.9	0.00	0.00	0.12	0.30	1.25	3.22	0.39	1.01	0.00	0.00	1.32	3.39
99%	38.3	0.11	0.28	0.00	0.00	1.52	3.97	0.00	0.00	0.29	0.77	1.55	4.05
100%	37.1	0.00	0.00	0.00	0.00	1.05	2.84	0.00	0.00	0.28	0.77	1.09	2.94

Table 17 Overall mean, standard deviations and coefficients of variation (%) for cycle threshold, NG panel members 2, 3, and 4

Hit Rate	Mean Ct	Between instrument		Between lot		Within run		Between run		Between day		Total	
		SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%	SD	CV%
Endocervical Swab in cobas [®] PCR Media													
44%	39.1	0.00	0.00	0.31	0.79	0.84	2.14	0.72	1.85	0.57	1.46	1.28	3.28
94%	38.1	0.00	0.00	0.00	0.00	1.27	3.34	0.00	0.00	0.00	0.00	1.27	3.34
100%	36.5	0.00	0.00	0.24	0.67	0.69	1.89	0.00	0.00	0.15	0.40	0.74	2.04
Cervical Samples collected into PreservCyt [®] Solution													
65%	39.0	0.34	0.87	0.00	0.00	1.11	2.85	0.08	0.20	0.45	1.16	1.25	3.21
96%	38.0	0.00	0.00	0.00	0.00	1.25	3.28	0.00	0.00	0.00	0.00	1.25	3.28
100%	35.8	0.00	0.00	0.28	0.78	0.76	2.13	0.00	0.00	0.00	0.00	0.81	2.27
cobas [®] PCR Media with Urine													
78%	39.1	0.00	0.00	0.26	0.66	1.35	3.46	0.00	0.00	0.18	0.45	1.39	3.55
100%	36.7	0.14	0.38	0.16	0.42	0.71	1.92	0.00	0.00	0.00	0.00	0.74	2.00
100%	34.9	0.00	0.00	0.16	0.47	0.37	1.06	0.06	0.18	0.00	0.00	0.41	1.17

Analytical specificity/cross reactivity

A panel of 151 bacteria, fungi and viruses, including those commonly found in the male and female urogenital tract, 17 representatives of non-gonorrhoeae *Neisseria* strains and other phylogenetically unrelated organisms, were tested with cobas® CT/NG to assess analytical specificity. The organisms listed in Table 18 were spiked at concentrations of approximately 1×10^6 units*/mL for bacteria and approximately 1×10^5 units*/mL for viruses into pools of negative swab specimens in cobas® PCR Media (endocervical, oropharyngeal, and anorectal), urine stabilized in cobas® PCR Media and cervical specimens in PreservCyt® Solution. Testing was performed with each potential interfering organism alone as well as with each organism mixed with CT and NG cultures at ≤ 12 EB/mL and ≤ 1.2 CFU/mL. Results indicated that none of these organisms interfered with the detection of CT and NG or produced false positive results in the CT/NG negative matrices.

*All bacteria were quantified as Colony Forming Units (CFU) except *Chlamydomydia pneumonia* and *Chlamydomydia psittaci* as Elementary Bodies (EB). All viruses were quantified as units/mL as determined by TCID₅₀ Endpoint Dilution Assay. *Trichomonas vaginalis* and HPV16 were quantified as cells/mL.

Table 18 Microorganisms tested for analytical specificity/cross reactivity

<i>Achromobacter xerosis</i>	<i>Haemophilus ducreyi</i>	<i>Neisseria polysaccharea</i>
<i>Acinetobacter calcoaceticus</i>	<i>Haemophilus influenzae</i>	<i>Neisseria sicca</i>
<i>Acinetobacter lwoffii</i>	<i>Helicobacter pylori</i>	<i>Neisseria subflava</i>
<i>Actinomyces israelii</i>	HPV 16	<i>Neisseria weaverii</i>
<i>Actinomyces pyogenes</i>	HSV-1	<i>Paracoccus denitrificans</i>
<i>Aerococcus viridans</i>	HSV-2	<i>Peptostreptococcus anaerobius</i>
<i>Aeromonas hydrophila</i>	Human Adenovirus 40	<i>Peptostreptococcus asaccharolyticus</i>
<i>Alcaligenes faecalis</i>	Human Enterovirus 71	<i>Peptostreptococcus magnus</i>
<i>Bacillus subtilis</i>	Human Rotavirus	<i>Plesiomonas shigelloides</i>
<i>Bacteriodes fragilis</i>	<i>Kingella dentrificans</i>	<i>Propionibacterium acnes</i>
<i>Bacteroides caccae</i>	<i>Kingella kingae</i>	<i>Proteus mirabilis</i>
<i>Bacteroides ureolyticus</i>	<i>Klebsiella oxytoca</i>	<i>Proteus penneri</i>
<i>Bifidobacterium adolescentis</i>	<i>Klebsiella pneumoniae</i>	<i>Proteus vulgaris</i>
<i>Bifidobacterium breve</i>	<i>Lactobacillus acidophilus</i>	<i>Providencia rettgeri</i>
<i>Bifidobacterium longum</i>	<i>Lactobacillus brevis</i>	<i>Providencia stuartii</i>
<i>Blautia producta</i>	<i>Lactobacillus crispatus</i>	<i>Pseudomonas aeruginosa</i>
<i>Branhamella catarrhalis</i>	<i>Lactobacillus delbrueckii subsp. lactis</i>	<i>Pseudomonas fluorescens</i>
<i>Brevibacterium linens</i>	<i>Lactobacillus jensenii</i>	<i>Pseudomonas putida</i>
<i>Campylobacter coli</i>	<i>Lactobacillus lactis</i>	<i>Rahnella aquatilis</i>
<i>Campylobacter jejuni</i>	<i>Lactobacillus oris</i>	<i>Rhizobium radiobacter</i>
<i>Candida albicans</i>	<i>Lactobacillus parabuchneri</i>	<i>Rhodospirillum rubrum</i>
<i>Candida glabrata</i>	<i>Lactobacillus reuteri</i>	<i>Saccharomyces cerevisiae</i>
<i>Candida parapsilosis</i>	<i>Lactobacillus vaginalis</i>	<i>Salmonella choleraesuis</i>
<i>Candida tropicalis</i>	<i>Lactococcus lactis cremoris</i>	<i>Salmonella minnesota</i>
<i>Chlamydia psittaci</i>	<i>Legionella pneumophila</i>	<i>Salmonella typhimurium</i>
<i>Chlamydomydia pneumoniae</i>	<i>Leuconostoc paramensenteroides</i> aka. <i>Weissella</i>	<i>Serratia denitrificans</i>
<i>Chromobacter violaceum</i>	<i>Listeria monocytogenes</i>	<i>Serratia marcescens</i>
<i>Citrobacter freundii</i>	<i>Micrococcus luteus</i>	<i>Shigella dysenteriae</i>

<i>Clostridioides difficile</i> (Serogroup B)	<i>Moraxella lacunata</i>	<i>Staphylococcus aureus</i>
<i>Clostridium perfringens</i>	<i>Moraxella osloensis</i>	<i>Staphylococcus epidermidis</i>
<i>Corynebacterium genitalium</i>	<i>Morganella morganii</i>	<i>Staphylococcus saprophyticus</i>
<i>Corynebacterium xerosis</i>	<i>Mycobacterium smegmatis</i>	<i>Streptococcus agalactiae</i>
<i>Cryptococcus neoformans</i>	<i>Mycoplasma genitalium</i>	<i>Streptococcus anginosus</i>
<i>Cytomegalovirus</i>	<i>Mycoplasma hominis</i>	<i>Streptococcus bovis</i>
<i>Deinococcus radiodurans</i>	<i>Neisseria cinerea</i>	<i>Streptococcus dysgalactiae</i>
<i>Derxia gummosa</i>	<i>Neisseria dentrificans</i>	<i>Streptococcus equinus</i>
<i>Eikenella corrodens</i>	<i>Neisseria elongata</i> subsp. <i>elongata</i>	<i>Streptococcus mitis</i>
<i>Enterobacter aerogenes</i>	<i>Neisseria elongata</i> subsp. <i>niroreducans</i>	<i>Streptococcus mutans</i>
<i>Enterobacter cloacae</i>	<i>Neisseria flava</i>	<i>Streptococcus pneumoniae</i>
<i>Enterococcus avium</i>	<i>Neisseria flavescens</i>	<i>Streptococcus pyogenes</i>
<i>Enterococcus casseliflavus</i>	<i>Neisseria kochi</i>	<i>Streptococcus salivarius</i>
<i>Enterococcus faecalis</i>	<i>Neisseria lactamica</i>	<i>Streptococcus sanguis</i>
<i>Enterococcus faecium</i>	<i>Neisseria macacae</i>	<i>Streptomyces griseinus</i>
<i>Erwinia herbicola</i>	<i>Neisseria meningitidis</i> Serogroup A	<i>Trichomonas vaginalis</i>
<i>Erysipelothrix rhusiopathiae</i>	<i>Neisseria meningitidis</i> Serogroup B	<i>Ureaplasma urealyticum</i>
<i>Escherichia coli</i>	<i>Neisseria meningitidis</i> Serogroup C	<i>Veillonella parvula</i>
<i>Escherichia fergusonii</i>	<i>Neisseria meningitidis</i> Serogroup D	<i>Vibrio cholerae</i>
<i>Flavobacterium meningosepticum</i>	<i>Neisseria meningitidis</i> Serogroup W135	<i>Vibrio parahaemolyticus</i>
<i>Fusobacterium nucleatum</i>	<i>Neisseria meningitidis</i> Serogroup Y	<i>Yersinia enterocolitica</i>
<i>Gardnerella vaginalis</i>	<i>Neisseria mucosa</i>	-
<i>Gemella haemolysans</i>	<i>Neisseria perflava</i>	-

Interference

The effect of over-the-counter or prescription feminine products that may be present in urogenital specimens (Table 19), over-the-counter oral hygiene products that may be present in oropharyngeal specimens (Table 20) and of hygiene and prescription products that may be present in anorectal specimens (Table 21) were evaluated. Testing was done using pooled clinical specimens (vaginal swab, urine and PreservCyt® specimens were used to represent urogenital) with spiking of potential interferents at levels expected from normal patient usage. Interferents were tested in CT/NG negative specimen pools as well as in specimen pools with CT/NG at ≤ 120 EB/mL and ≤ 1.2 CFU/mL, depending on the specimen type tested. CT serovars D and I and NG strains 2948 (ATCC 19424) and 891 were used in this study.

Of the over-the-counter (OTC) feminine hygiene and prescription products tested in urogenital specimens, Metronidazole, Replens, RepHresh Odor Eliminating Vaginal Gel and RepHresh Clean Balance produced false negative or invalid results. These products contain carbomer(s). Products containing carbomer(s) have been shown to generate false negative and invalid results. Table 19 is not intended to be a comprehensive list of carbomer containing products. None of the OTC oral hygiene products tested in oropharyngeal swabs or the OTC anorectal hygiene and prescription products tested in anorectal swabs produced interference to the test when examined at concentrations expected through typical product use.

Table 19 List of substances tested for interference in urogenital specimens

Product Name	
Clindamycin Phosphate Vaginal Cream	Norforms Suppositories
CVS Tioconazole 1 (Equate tioconazole 1)	Premarin
Equate Vagaine Anti-Itch Cream	Replens Long-Lasting Vaginal Moisturizer*
Estrace	Summer's Eve Feminine Deodorant Spray
K-Y Ultra Gel (Replaces K-Y Silk E)	VCF - Vaginal Contraceptive Foam
Metronidazole Vaginal Gel *	Yeast Gard Advanced
Monistat 3 Vaginal Antifungal Combination Pack	Azo Standard (urine only)
Monistat Complete Care Itch Relief Cream	RepHresh Odor Eliminating Vaginal Gel**†
Gyne-Lotrimin 7	RepHresh Clean Balance**†

* Metronidazole, Replens and RepHresh showed interference at levels that may potentially be present in clinical specimens

† RepHresh products were tested using simulated swab specimen

Table 20 List of substances tested for interference in oropharyngeal swab specimens

Product Name
Cepacol Maximum Strength Throat Drop Lozenges
Colgate Total Toothpaste
Robitussin Cough / Chest Congestion Cough Syrup
Listerine Ultra Clean Antiseptic Mouthwash
Scope Mouthwash
Sucrets Complete Lozenges
Vicks - Chloraseptic Sore Throat Spray Menthol
Zicam Oral Mist

Table 21 List of substances tested for interference in anorectal swab specimens

Product Name
ANUSOL® Plus Ointment
CB Fleet® Mineral Oil Enema
Doproct Suppositories/ Hemorrhoidal Treatment
K-Y Jelly
Lotrimin Antifungal Cream
Preparation H Hemorrhoidal Ointment
PREPARATION H Hemorrhoidal Suppositories
Driminate Generic for Dramamine Motion Sickness - Major Pharmaceuticals
Target - Triple Paste Diaper Rash Ointment
Tucks Medicated Cooling Hemorrhoidal Pads
Vaseline Original Petroleum Jelly

Endogenous substances that may be present in urogenital, oropharyngeal and anorectal specimens were tested for interference. Testing was done using pooled clinical specimens (endocervical swab, urine and PreservCyt® specimens were used to represent urogenital) with spiking of potential endogenous interferents. Interferents were tested in CT/NG negative specimen pools as well as in the presence of CT/NG at ≤ 120 EB/mL and ≤ 1.2 CFU/mL, depending on the specimen type tested. CT serovars D and I and NG strains 2948 (ATCC 19424) and 891 were used in this study.

Interference was noted with whole blood at 10% for urine and PreservCyt® specimens, with stool at 0.4% in anorectal specimens and with cervical mucus at 1% in endocervical specimens. Levels of endogenous substances tolerated by the assay for all specimen types are shown in Table 22.

Table 22 Summary of endogenous substance concentrations that do not show interference

Interferent	Endocervical Swab	Anorectal Swab	Oropharyngeal Swab	PreservCyt®	Urine
Albumin (% w/v)	N/A	N/A	N/A	N/A	5%
Bilirubin (% w/v)	N/A	N/A	N/A	N/A	0.5%
Mucus (% w/v)	0.5%	1.0%	1.0%	1.0%	0.5%
Glucose (% w/v)	N/A	N/A	N/A	N/A	1.0%
Peripheral Blood Mononuclear Cells (PBMCs as cells/mL)	1.0E+06	1.0E+06	1.0E+06	1.0E+06	1.0E+06
pH (acidic and alkaline)	N/A	N/A	N/A	N/A	pH 4 and pH 9
Saliva (% w/v)	N/A	N/A	2.0%	N/A	N/A
Semen (% w/v)	1.5%	N/A	N/A	1.5%	N/A
Stool (% w/v)	N/A	0.3%	N/A	N/A	N/A
Whole Blood (% v/v)	10%	10%	10%	5%	5%

Competitive inhibition

To assess competitive inhibition between CT and NG, samples of each specimen type (vaginal, oropharyngeal, and anorectal swabs in **cobas**® PCR Media, urine stabilized in **cobas**® PCR Media and cervical specimens in PreservCyt® Solution) were tested where low and moderate concentrations of one target were mixed with very high concentrations of the opposite target. Low and moderate concentrations were defined as ~1x LoD and ~3x LoD, respectively, and high concentrations were defined as generating a signal greater than in 95% of target positive specimens.

Testing results indicated that when NG was present at a high concentration, CT was detected in all specimen types, at both low (~1x LoD) and moderate (~3x LoD) levels. Results also indicated that when CT was present at a high concentration, NG was detected in all specimen types at moderate (~3x LoD) levels, and in all but one (oropharyngeal) specimen type, at low (~1x LoD) levels.

Whole system failure

The samples tested in the whole system failure study were pooled CT and NG negative clinical cervical specimens collected in PreservCyt® Solution, vaginal swab specimens collected in **cobas**® PCR Media and urine specimens stabilized in **cobas**® PCR Media. Each pool of clinical specimens was spiked with cultures of CT, serovar D (D-UW3) (CT) and NG 2948 (ATCC 19424) (NG) to a concentration of ≤ 12 EB/mL and ≤ 1.2 CFU/mL, depending on the sample type. The results of this study determined that all replicates were valid and positive for CT/NG, resulting in a whole system failure rate of 0%. The two-sided 95% exact confidence interval was 0% for the lower bound and 3.6% for the upper bound [0%: 3.6%].

Cross contamination

Studies were performed to evaluate potential cross contamination on the cobas® 6800/8800 Systems using cobas® CT/NG. Cross-contamination can cause false positive results. In this performance study the sample to sample cross-contamination rate of cobas® CT/NG has been determined to be 0.5% (2/432) when alternating very high positive and negative samples were tested over multiple runs. Run to run cross-contamination has not been observed (0/282). Testing was done using samples prepared with cobas® PCR Media, urine stabilized in cobas® PCR Media and with PreservCyt® Solution. High positive samples in the study were prepared to generate a Ct value that exceeds 95% or more of signal obtained from specimens of infected patients in the intended use population. The likelihood of encountering such specimens in the routine use of cobas® CT/NG is proportional to CT and NG prevalence in the testing population. Therefore the sample to sample cross-contamination rate in routine use of cobas® CT/NG will likely be less than $0.5\% \times 5\% \times \text{CT prevalence in the testing population}$. Even at a maximum prevalence of 100%, the cross-contamination rate would be $0.5\% \times 5\% \times 100\% = 0.025\%$.

Clinical performance using clinical specimens

Prospective collection method correlation

The performance of cobas® CT/NG and the cobas® 4800 CT/NG Test were compared by analysis of the following specimen types:

- Endocervical swabs in cobas® PCR Media
- Vaginal swabs (clinician-collected) in cobas® PCR Media
- Vaginal swabs (self-collected) in cobas® PCR Media
- Oropharyngeal swabs in cobas® PCR Media
- Anorectal swabs in cobas® PCR Media
- Male and female urine mixed with cobas® PCR Media
- Cervical specimens collected in PreservCyt® Solution

A total of 6,318 subjects were recruited from 19 clinical sites in Germany and the US, producing 13,433 valid CT results and 13,398 valid NG results which were used for the correlation study analysis. The correlation results for all specimen types are shown in Table 23 and the calculated PPA, NPA, OPA with 95% Confidence Intervals are shown in Table 24. Across all specimen types, there were 125 discrepant specimens for *Chlamydia trachomatis*; of which 120 were positive on the 6800/8800 Systems and 5 were positive on the 4800 System. Also across all specimen types, there were 42 discrepant specimens for *N. gonorrhoeae*, of which 40 were positive on the 6800/8800 Systems and 2 were positive on the cobas® 4800 System.

Correlation analysis between cobas® CT/NG and the cobas® 4800 CT/NG Test shows Positive Percent Agreements (PPA) greater than 95% for both CT and NG in all specimen types with the majority of specimen types having a PPA of 100% for both CT and NG. Negative and Overall Percent Agreements were greater than 98% for both CT and NG in all specimen types.

Table 23 Results summary for correlation of cobas® CT/NG and the cobas® 4800 CT/NG Test

Specimen Type	Chlamydia trachomatis				Neisseria gonorrhoeae			
	Con +	Con -	68+/48-	68-/48+	Con +	Con -	68+/48-	68-/48+
Endocervical Swab	114	1778	15	0	22	1883	1	1
Vaginal Swab	87	1040	15	0	20	1111	1	0
SC-Vaginal Swab	90	1028	14	0	18	1100	3	0
Oropharyngeal Swab	37	1915	14	0	74	1864	22	0
Anorectal Swab	100	1871	30	0	71	1923	8	0
Female Urine	272	2083	18	0	23	2340	4	0
Male Urine	114	717	3	0	30	803	0	1
PreservCyt®	157	1905	11	5	25	2049	1	0
All Specimens Total	971	12337	120	5	283	13073	40	2

Con = Concordant; + = Positive; - = Negative; SC = Self-Collected

Table 24 Agreement calculations for correlation of cobas® CT/NG and the cobas® 4800 CT/NG Test

Specimen Type	Chlamydia trachomatis			Neisseria gonorrhoeae		
	Result (%)		95% CI	Result		95% CI
Endocervical Swab	PPA	100%	96.8%-100%	PPA	95.7%	78.1%-99.9%
	NPA	99.2%	98.6%-99.5%	NPA	99.9%	99.7%-100%
	OPA	99.2%	98.7%-99.6%	OPA	99.9%	99.6%-100%
Vaginal Swab	PPA	100%	95.8%-100%	PPA	100%	83.2%-100%
	NPA	98.6%	97.7%-99.2%	NPA	99.9%	99.5%-100%
	OPA	98.7%	97.8%-99.3%	OPA	99.9%	99.5%-100%
SC-Vaginal Swab	PPA	100%	96.0%-100%	PPA	100%	81.5%-100%
	NPA	98.7%	97.8%-99.3%	NPA	99.7%	99.2%-99.9%
	OPA	98.8%	97.9%-99.3%	OPA	99.7%	99.2%-99.9%
Oropharyngeal Swab	PPA	100%	90.5%-100%	PPA	100%	95.1%-100%
	NPA	99.3%	98.8%-99.6%	NPA	98.8%	98.2%-99.3%
	OPA	99.3%	98.8%-99.6%	OPA	98.9%	98.3%-99.3%
Anorectal Swab	PPA	100%	96.4%-100%	PPA	100%	94.9%-100%
	NPA	98.4%	97.8%-98.9%	NPA	99.6%	99.2%-99.8%
	OPA	98.5%	97.9%-99.0%	OPA	99.6%	99.2%-99.8%
Female Urine	PPA	100%	98.7%-100%	PPA	100%	85.2%-100%
	NPA	99.1%	98.6%-99.5%	NPA	99.8%	99.6%-100%
	OPA	99.2%	98.8%-99.5%	OPA	99.8%	99.6%-100%
Male Urine	PPA	100%	96.8%-100%	PPA	96.8%	83.3%-99.9%
	NPA	99.6%	98.8%-99.9%	NPA	100%	99.5%-100%
	OPA	99.6%	99.0%-99.9%	OPA	99.9%	99.3%-100%
PreservCyt®	PPA	96.9%	92.9%-99.0%	PPA	100%	86.3%-100%
	NPA	99.4%	99.0%-99.7%	NPA	99.9%	99.7%-100%
	OPA	99.2%	98.8%-99.6%	OPA	99.9%	99.7%-100%
All Specimens Total	PPA	99.5%	98.8%-99.8%	PPA	99.3%	97.5%-99.9%
	NPA	99.0%	98.8%-99.2%	NPA	99.7%	99.6%-99.8%
	OPA	99.1%	98.9%-99.2%	OPA	99.7%	99.6%-99.8%

PPA = Positive Percent Agreement; NPA = Negative Percent Agreement; OPA = Overall Percent Agreement; SC = Self-Collected

Clinical study - Prospective collection of urogenital specimens

The clinical utility and performance of cobas® CT/NG was established in a multi-site, prospective collection study by comparing the results to an Infection Status (IS) that used a combination of FDA-cleared NAATs for urogenital specimens. Female and male urogenital specimens were collected at 9 geographically diverse sites in the US with testing performed at 4 laboratory testing sites (3 external and 1 internal).

Prospectively enrolled female subjects provided the following urogenital specimens: first-void urine, 3 vaginal swabs, 1 endocervical swab in cobas® PCR Media, and 1 cervical sample in PreservCyt® Solution. If the female was in the clinician-collected vaginal swab arm of the study, 2 of the vaginal swabs were placed in the respective manufacturers'

collection device and 1 in **cobas**® PCR Media. If the female subject was in the self-collected vaginal swab self-collection arm of the study, then 1 vaginal swab was self-collected first and placed into **cobas**® PCR Media and then followed by the 2 clinician-collected vaginal swabs and placed in the 2 respective manufacturers' collection devices.

Prospectively enrolled male subjects provided a urine specimen that was aliquoted into the respective manufacturers' collection device and **cobas**® PCR Media.

Subjects were classified as symptomatic if they self-reported symptoms indicative of a CT or NG infection as listed below:

- Dysuria (pain during urination)
- Coital pain, difficulty or bleeding
- Pelvic pain
- Abnormal vaginal discharge
- Pelvic, uterine or ovarian pain
- Urethral discharge
- Testicular pain
- Scrotal pain or swelling

Prospectively enrolled subjects were classified as asymptomatic if they did not report any of the above symptoms.

Specimens were tested for CT and NG using **cobas**® CT/NG and commercially available NAATs. All tests were run according to the respective manufacturers' Instructions For Use.

The clinical performance of **cobas**® CT/NG was evaluated by comparing the results from collected specimen types to a pre-specified IS algorithm as determined by the combined results from 2 commercially available NAATs for females and 3 commercially available NAATs for males. The IS algorithms for female and male subjects are shown in Table 25 and Table 26, respectively.

For NG, archived prospectively collected female urine, cervical specimens in PreservCyt®, and endocervical swabs were obtained from the clinical study for **cobas**® CT/NG v2 test on the **cobas**® 4800 System. The IS of these specimens were already determined from the clinical study for **cobas**® CT/NG v2 test on the **cobas**® 4800 System.

Table 25 Determination of female Infection Status (IS) for urogenital specimens^a

NAAT1 Urine/Vaginal	NAAT2 Urine/Vaginal	Infection Status (IS) ^b
+/+	+/+	Infected
+/+	+/- or -/+	Infected
+/- or -/+	+/+	Infected
+/-	-/+	Infected
-/+	+/- or -/+	Infected
+/-	+/-	Infected (Urine) Non-Infected (Vaginal)
+/- or -/+	-/-	Not Infected
+/+	-/-	Not Infected
-/-	+/+	Not Infected
-/-	+/- or -/+	Not Infected
-/-	-/-	Not Infected

^aOne or more positives in each NAAT (NAAT1 and NAAT2) designates the IS as positive. Any other combination of results defines the IS as negative.

^bIn the scenario where one or more of the sample types are invalid, the remaining sample types with valid results from NAAT1 and NAAT2 must have concordant positive or concordant negative results to determine the IS as Infected or Not Infected, respectively. For all other cases where one or more of the sample types are invalid, the IS is indeterminate.

Table 26 Determination of male Infection Status (IS) for urine specimens

NAAT1 Urine	NAAT2 Urine	NAAT3 Urine	Infection Status (IS) ^a
+	+	+	Infected
+	+	-	Infected
+	-	+	Infected
-	+	+	Infected
-	-	+	Not Infected
-	+	-	Not Infected
+	-	-	Not Infected
-	-	-	Not Infected

^aIf at least 2 out of the 3 test results are concordant positive or negative then the IS can be considered as infected or non-infected, respectively. If one test result is invalid/missing and the other two test results are discordant then the IS is indeterminate. If 2 or 3 test results are invalid/missing, then the IS is indeterminate.

Sensitivity (SENS), specificity (SPEC), positive predictive value (PPV), and negative predictive value (NPV) of cobas® CT/NG were calculated separately for the detection of CT or NG using the IS as the composite reference standard and evaluated by gender, sample type, and symptom status. In addition, the predictive values were calculated based on overall sensitivity and specificity (with all data combined for males and females) for a range of hypothetical prevalence values.

Clinical study – Prospective collection of extra-genital specimens

The clinical utility and performance of **cobas**® CT/NG was established in a multi-site, prospective collection study by comparing the results to an Infection Status (IS) that used a combination of commercially available CT/NG assays using anorectal or oropharyngeal swab samples. The subjects were enrolled from 8 geographically diverse clinic sites (STD, HIV, Family Planning, and STD Research). Specimens were tested for CT and NG using **cobas**® CT/NG and commercially available NAATs. All tests were run according to the respective manufacturers' Instructions For Use. The clinical performance of **cobas**® CT/NG was determined by comparing the results to the IS. A positive IS interpretation was derived when at least 2 of the 3 comparator reference assays were positive. The IS interpretations are further outlined in Table 27 below.

Table 27 Comparator interpretation of Infection Status (IS) from “NAAT A” NAAT B” NAAT C” results for each specimen type

NAAT A	NAAT B	NAAT C	IS Interpretation
+	+	+	+
+	+	-	+
+	-	+	+
-	+	+	+
U	+	+	+
+	U	+	+
+	+	U	+
+	-	-	-
-	+	-	-
-	-	+	-
-	-	-	-
+	+	+	+
+	+	-	+
+	-	+	+
-	+	+	+
+	-	-	-
-	+	-	-
-	-	+	-
-	-	-	-
U	-	-	-
-	U	-	-
-	-	U	-
+	U	-	U
+ or -	U	U	U

IS = Infection status; + denotes Positive, - denotes Negative ; U = uninterpretable test result.

Note: Uninterpretable test results occurred when retesting of invalid or equivocal results failed to yield a positive or negative result.

Results

Urogenital specimens – Clinical study

A total of 5,197 subjects were prospectively enrolled, of which 5,105 were eligible for inclusion. Of the 5,105 eligible subjects contributing prospective specimens, 5,053 (99.0%) (3,860 females and 1,193 males) were evaluable and were included in the data analyses. A total of 52 subjects (1.0%) were classified as non-evaluable and excluded from all statistical analyses. There were a total of 371 archived prospectively collected female urogenital samples (urine, cervical specimens in PreservCyt, and endocervical swabs) tested in this clinical study from 295 female subjects. Among the 17,169 samples tested in this study, 19 samples exhibited invalid results on the first run (invalid rate of 0.11% (95%CI: 0.07%; 0.17%)). Upon repeat testing, 3 samples exhibited valid results.

Extragenital specimens – Clinical study

A total of 2,439 subjects were consented to participate in this study, however, a total of 49 subjects were excluded, based on exclusion/inclusion criteria, that led to a total subject enrollment of 2,390. Of the 2,390 subjects contributing specimens, 2,365 anorectal and 2,382 oropharyngeal specimens were tested. Out of the 4,747 samples (2,365 rectal swabs and 2,382 oropharyngeal swabs), there were 4 final invalid results due to processing errors.

Chlamydia trachomatis: Urogenital specimens infection status summary

Table 28 and Table 29 summarize the results from symptomatic and asymptomatic, prospectively enrolled subjects designated as infected or non-infected with CT (females and males, respectively) according to the IS algorithm. A total of 271 females and 118 males were infected with CT. Symptoms were reported in 45.8% (124/271) of infected and 36.7% (1318/3589) of non-infected females. Symptoms were reported in 53.4% (63/118) of infected and 22.5% (242/1074) of non-infected males.

Table 28 CT positive/negative analyses for female Infected Status (IS)

Infection Status	NAAT1 UR	NAAT1 VS	NAAT2 UR	NAAT2 VS	cobas® CT/NG UR	cobas® CT/NG VS	cobas® CT/NG PC	cobas® CT/NG ES	SS ^a Symp. ^c	SS ^a Asymp. ^c	Total
Infected	+	+	+	+	+	+	+	+	104	108	212
Infected	-	+	+	+	+	+	+	+	2	7	9
Infected	+	+	+	+	+	+	-	+	1	5	6
Infected	+	+	-	+	+	+	+	+	2	4	6
Infected	+	+	+	+	+	+	-	-	1	4	5
Infected	+	+	+	+	+	+	+	-	1	3	4
Infected	-	+	+	+	-	+	+	+	1	3	4
Infected	-	+	-	+	-	+	+	+	2	2	4
Infected	-	+	-	+	+	+	+	+	2	1	3
Infected	+	-	+	+	+	+	-	-	1	1	2
Infected	+	+	+	+	+	+	Failed	+	0	1	1
Infected	+	+	+	+	+	+	+	Failed	1	0	1
Infected	-	+	+	+	+	-	+	+	0	1	1
Infected	-	+	+	+	+	+	+	-	0	1	1

Infection Status	NAAT1 UR	NAAT1 VS	NAAT2 UR	NAAT2 VS	cobas® CT/NG UR	cobas® CT/NG VS	cobas® CT/NG PC	cobas® CT/NG ES	SS ^a Symp. ^c	SS ^a Asymp. ^c	Total
Infected	-	+	+	+	+	+	-	+	1	0	1
Infected	-	+	+	+	+	+	-	-	0	1	1
Infected	-	+	+	+	-	+	-	-	1	0	1
Infected	-	+	-	+	+	+	+	-	0	1	1
Infected	-	+	-	+	-	+	-	+	0	1	1
Infected	+	-	+	+	+	+	+	+	1	0	1
Infected	+	-	+	+	+	-	-	-	0	1	1
Infected	+	-	-	+	-	+	-	-	1	0	1
Infected	+	-	-	+	-	-	-	-	0	1	1
Infected ^b	+	-	+	-	+	+	-	+	1	0	1
Infected ^b	+	-	+	-	+	+	-	-	1	0	1
Infected ^b	+	-	+	-	+	-	-	-	0	1	1
Total									124	147	271
Non-Infected	-	-	-	-	-	-	-	-	1252	2165	3417
Non-Infected	-	-	-	+	-	-	-	-	6	12	18
Non-Infected	-	Invalid	-	-	-	-	-	-	7	5	12
Non-Infected	-	-	-	-	-	Invalid	-	-	6	4	10
Non-Infected	-	-	-	-	-	+	-	-	1	9	10
Non-Infected	-	-	+	-	-	-	-	-	2	7	9
Non-Infected	-	-	-	-	-	-	-	+	5	4	9
Non-Infected	-	-	NA	-	-	-	-	-	2	7	9
Non-Infected	-	-	Invalid	-	-	-	-	-	0	9	9
Non-Infected	-	-	-	-	-	-	-	NA	3	5	8
Non-Infected	+	-	-	-	-	-	-	-	3	3	6
Non-Infected	-	-	-	-	+	-	-	-	1	5	6
Non-Infected	-	+	-	-	-	-	-	-	2	2	4
Non-Infected	-	-	-	-	-	-	+	-	1	3	4
Non-Infected	-	-	-	-	-	NA	-	-	1	3	4
Non-Infected	-	NA	-	-	-	-	-	-	0	4	4
Non-Infected	-	-	-	-	-	-	NA	NA	0	3	3
Non-Infected	-	-	-	NA	-	-	-	-	1	2	3
Non-Infected	NA	-	-	-	-	-	-	-	0	3	3
Non-Infected	Invalid	-	-	-	-	-	-	-	2	1	3
Non-Infected	-	+	-	-	-	+	-	-	2	0	2
Non-Infected	-	-	-	+	-	+	+	+	0	2	2
Non-Infected	-	-	-	+	-	+	+	-	2	0	2
Non-Infected	-	-	-	+	-	+	-	+	1	1	2
Non-Infected	-	-	-	+	-	+	-	-	0	2	2
Non-Infected	-	-	-	-	-	+	+	+	2	0	2
Non-Infected	-	-	-	-	-	-	-	Invalid	2	0	2
Non-Infected	-	-	-	Invalid	-	-	-	-	1	1	2

Infection Status	NAAT1 UR	NAAT1 VS	NAAT2 UR	NAAT2 VS	cobas® CT/NG UR	cobas® CT/NG VS	cobas® CT/NG PC	cobas® CT/NG ES	SS ^a Symp. ^c	SS ^a Asymp. ^c	Total
Non-Infected	-	-	+	+	-	+	-	-	0	1	1
Non-Infected	-	-	+	-	+	-	-	-	0	1	1
Non-Infected	-	-	+	-	-	+	-	-	1	0	1
Non-Infected	-	-	-	+	+	+	+	+	0	1	1
Non-Infected	-	-	-	+	-	-	+	+	1	0	1
Non-Infected	-	-	-	+	+	+	-	+	0	1	1
Non-Infected	-	-	-	+	-	-	-	+	0	1	1
Non-Infected	-	-	-	+	+	+	-	-	0	1	1
Non-Infected	-	-	-	-	-	-	NA	-	0	1	1
Non-Infected	-	-	-	-	-	Invalid	Invalid	Invalid	1	0	1
Non-Infected	-	-	-	-	-	-	Invalid	Invalid	1	0	1
Non-Infected	-	-	-	-	-	NA	Invalid	-	1	0	1
Non-Infected	-	-	-	-	-	-	Invalid	-	1	0	1
Non-Infected	-	-	-	-	-	+	+	-	1	0	1
Non-Infected	-	-	-	-	-	-	-	Failed	1	0	1
Non-Infected	-	-	-	-	+	-	-	+	1	0	1
Non-Infected	-	-	-	-	-	+	-	+	1	0	1
Non-Infected	-	-	-	-	Failed	-	-	-	1	0	1
Non-Infected	-	-	-	-	-	Failed	-	-	1	0	1
Non-Infected	-	-	-	Invalid	-	+	+	+	0	1	1
Non-Infected	-	-	NA	+	-	+	-	-	0	1	1
Non-Infected	-	Invalid	-	-	-	Invalid	-	-	1	0	1
Total									1318	2271	3589

^a SS = symptom status

^b Infected (Urine), Non-Infected (Swabs).

^c Symp = symptomatic, Asymp = asymptomatic.

Note: In the scenario where one or more of the sample types are invalid/not available (NA), for female subjects, the remaining sample types with valid results from NAAT1 and NAAT2 must have concordant positive or concordant negative results to determine the IS as Infected or Not Infected, respectively. For all other cases where one or more of the sample types are invalid/not available (NA), the IS is indeterminate.

Note: Female subjects with designated infection status (Infected or Non-Infected) and final valid cobas® CT/NG test results are considered evaluable and included in this summary table.

Note: + denotes Positive, - denotes Negative, NA denotes Not Available.

Note: UR = urine, VS = vaginal swab, PC = PreservCyt®, ES = endocervical swab.

Note: cobas® Invalid are the sum of instrument amplification/detection errors and samples excluded due to protocol deviations.

Note: cobas® Failed are hardware, software or operator errors causing no result reported.

Table 29 CT positive/negative analysis for male Infection Status (IS)

Infection Status	NAAT1 UR	NAAT2 UR	NAAT3 UR	cobas® CT/NG UR	Symptom Status Symp ^a	Symptom Status Asymp ^a	Total
Infected	+	+	+	+	60	55	115
Infected	-	+	+	+	1	0	1
Infected	+	Invalid	+	+	1	0	1
Infected	+	-	+	+	1	0	1
Total Infected					63	55	118
Non-Infected	-	-	-	-	238	819	1057
Non-Infected	-	Invalid	-	-	2	2	4
Non-Infected	Invalid	-	-	-	0	3	3
Non-Infected	-	-	Invalid	-	0	3	3
Non-Infected	NA	-	-	-	1	1	2
Non-Infected	-	-	-	+	0	2	2
Non-Infected	-	-	+	-	0	1	1
Non-Infected	-	+	-	+	1	0	1
Non-Infected	+	-	-	-	0	1	1
Total Non-Infected					242	832	1074*

^aSymp = symptomatic, Asymp = asymptomatic.

*One subject had unknown symptom status and is not presented in this table.

Note: If at least 2 out of the 3 test results, for male subjects, are concordant positive or negative then the IS can be considered as infected or non-infected, respectively. If one test result is invalid/not available (NA) and the other two test results are discordant then the IS is indeterminate. If 2 or 3 test results are invalid/not available, then the IS is indeterminate.

Note: Male subjects with designated patient infection status (Infected or Non-Infected) and final valid cobas® CT/NG test results are considered evaluable and included in this summary table.

Note: cobas® Invalid are the sum of instrument amplification/detection errors and samples excluded due to protocol deviations

Note: + denotes Positive, - denotes Negative, NA denotes Not Available.

Note: UR = urine.

***Chlamydia trachomatis*: Extragenital specimens infection status summary**

Table 30 summarizes the results from evaluable subjects designated as CT positive or negative according to the IS algorithm for both Anorectal (AR) and Oropharyngeal (OP) specimens. Of the 2,365 contributing subjects for rectum, 18 subjects had CT uninterpretable IS, 12 were excluded due to protocol deviations and the remaining 2,335 were evaluable. Similarly, of the 2,382 contributing subjects for Oropharyngeal, 23 subjects had CT uninterpretable IS, 11 were excluded due to protocol deviations, 3 were excluded due to failed test results and the remaining 2,345 were evaluable.

Table 30 *Chlamydia trachomatis*: summary of Infection Status (IS) Interpretation for anorectal and oropharyngeal specimen types

Specimen Type ^a	NAAT A	NAAT B	NAAT C	IS ^b Interpretation	cobas® CT/NG	SS ^c Symp ^d	SS ^c Asymp ^d	SS ^c Unkn ^d	Total
AR	Inv	+	+	Positive	+	1	3	0	4
AR	-	+	+	Positive	-	0	3	0	3
AR	-	+	+	Positive	+	4	12	0	16
AR	+	-	+	Positive	-	0	1	0	1
AR	+	+	-	Positive	+	1	0	0	1
AR	+	+	+	Positive	-	2	1	0	3
AR	+	+	+	Positive	+	47	68	0	115
AR				Total Positive		55	88	0	143
AR	Inv	-	-	Negative	-	29	45	1	75
AR	-	NA	-	Negative	-	7	2	3	12
AR	-	NA	-	Negative	+	0	1	0	1
AR	-	Inv	-	Negative	-	3	3	0	6
AR	-	-	Inv	Negative	-	0	1	0	1
AR	-	-	Inv	Negative	+	1	0	0	1
AR	-	-	-	Negative	-	635	1,411	13	2,059
AR	-	-	-	Negative	+	5	2	0	7
AR	-	-	+	Negative	-	4	12	0	16
AR	-	-	+	Negative	+	0	6	0	6
AR	-	+	-	Negative	-	1	5	0	6
AR	-	+	-	Negative	+	1	1	0	2
AR				Total Negative		686	1,489	17	2,192
OP	Inv	+	+	Positive	+	0	1	0	1
OP	-	+	+	Positive	+	1	2	0	3
OP	+	+	-	Positive	+	0	1	0	1
OP	+	+	+	Positive	+	8	15	0	23
OP				Total Positive		9	19	0	28
OP	Inv	-	-	Negative	-	32	46	1	79
OP	-	NA	-	Negative	-	5	7	2	14
OP	-	Inv	-	Negative	-	1	6	0	7
OP	-	-	Inv	Negative	-	1	0	0	1
OP	-	-	-	Negative	-	679	1,486	14	2,179
OP	-	-	-	Negative	+	2	0	0	2
OP	-	-	+	Negative	-	13	16	0	29
OP	-	+	-	Negative	-	1	1	0	2
OP	-	+	-	Negative	+	0	2	0	2
OP	+	-	-	Negative	-	1	1	0	2
OP				Total Negative		735	1,565	17	2,317

^aAR = anorectal; OP=oropharyngeal^bIS = infection status.^cSS = symptom status;^dSymp = symptomatic, Asymp = asymptomatic, Unkn = Unknown symptom status.

Note: NA = Not available, Inv = Invalid.

Note: Infection Status (IS) is determined for each specimen type. The IS of a sample will be established by the concordance results from at least 2 out of 3 comparator assays (NAAT A, NAAT B, NAAT C). If one of the comparator assays is Uninterpretable/Invalid/Failed, the two remaining assays must be concordant to define the IS as Positive (+) or Negative (-). Any other combination of Uninterpretable/Invalid/Failed and valid results are excluded from the analyses.

Note: Of the 2,365 contributing subjects for Rectum, 18 subjects had CT uninterpretable IS. Similarly, of the 2,382 contributing subjects for Oropharyngeal, 23 subjects had CT uninterpretable IS.

Note: Any IS interpretation that is Uninterpretable/Invalid/Failed/Protocol deviations are excluded from performance analyses.

07997981001-07EN

***Chlamydia trachomatis*: performance results**

Sensitivity, specificity, and predictive values of cobas® CT/NG for CT as defined by IS are presented by gender, sample type, and symptom status in Table 31 for urogenital specimens and in Table 32 for extragenital specimens.

Table 31 CT clinical performance compared with Infection Status (IS) by gender, sample type, and symptom status

Gender	Sample Type ^a	Symptom Status ^b	Total (n)	SENS	95% Score CI	SPEC	95% Score CI	PREV (%)	PPV (%)	NPV (%)
Female	UR	Symp	1441	96.0% (119/124)	(90.9%, 98.3%)	99.8% (1315/1317)	(99.4%, 100.0%)	8.6	98.3	99.6
Female	UR	Asymp	2418	95.2% (140/147)	(90.5%, 97.7%)	99.6% (2262/2271)	(99.2%, 99.8%)	6.1	94.0	99.7
Female	UR	Overall	3859	95.6% (259/271) ^c	(92.4%, 97.4%)	99.7% (3577/3588)	(99.5%, 99.8%)	7.0	95.9	99.7
Female	VS-C	Symp	711	100.0% (63/63)	(94.3%, 100.0%)	99.2% (643/648)	(98.2%, 99.7%)	8.9	92.6	100.0
Female	VS-C	Asymp	1225	97.6% (83/85)	(91.8%, 99.4%)	99.0% (1129/1140)	(98.3%, 99.5%)	6.9	88.3	99.8
Female	VS-C	Overall	1936	98.6% (146/148)	(95.2%, 99.6%)	99.1% (1772/1788)	(98.6%, 99.4%)	7.6	90.1	99.9
Female	VS-S	Symp	720	100.0% (59/59)	(93.9%, 100.0%)	98.8% (653/661)	(97.6%, 99.4%)	8.2	88.1	100.0
Female	VS-S	Asymp	1186	98.4% (60/61)	(91.3%, 99.7%)	99.2% (1116/1125)	(98.5%, 99.6%)	5.1	87.0	99.9
Female	VS-S	Overall	1906	99.2% (119/120)	(95.4%, 99.9%)	99.0% (1769/1786)	(98.5%, 99.4%)	6.3	87.5	99.9
Female	PC	Symp	1438	95.1% (116/122)	(89.7%, 97.7%)	99.5% (1309/1316)	(98.9%, 99.7%)	8.5	94.3	99.5
Female	PC	Asymp	2413	90.3% (131/145)	(84.4%, 94.2%)	99.7% (2261/2268)	(99.4%, 99.9%)	6.0	94.9	99.4
Female	PC	Overall	3851	92.5% (247/267)	(88.7%, 95.1%)	99.6% (3570/3584)	(99.3%, 99.8%)	6.9	94.6	99.4
Female	ES	Symp	1433	95.9% (116/121)	(90.7%, 98.2%)	99.1% (1300/1312)	(98.4%, 99.5%)	8.4	90.6	99.6
Female	ES	Asymp	2410	91.1% (133/146)	(85.4%, 94.7%)	99.5% (2253/2264)	(99.1%, 99.7%)	6.1	92.4	99.4
Female	ES	Overall	3843	93.3% (249/267)	(89.6%, 95.7%)	99.4% (3553/3576)	(99.0%, 99.6%)	6.9	91.5	99.5
Male	UR	Symp	305	100.0% (63/63)	(94.3%, 100.0%)	99.6% (241/242)	(97.7%, 99.9%)	20.7	98.4	100.0
Male	UR	Asymp	887	100.0% (55/55)	(93.5%, 100.0%)	99.8% (830/832)	(99.1%, 99.9%)	6.2	96.5	100.0
Male	UR	Overall	1192*	100.0% (118/118)	(96.8%, 100.0%)	99.7% (1071/1074)	(99.2%, 99.9%)	9.9	97.5	100.0

^a UR = urine, VS-C = clinician-collected vaginal swab, VS-S = self-collected vaginal swab, PC = PreservCyt®, ES = endocervical swab.

^b Symp = symptomatic, Asymp = asymptomatic.

^c Five CT IS infected females had a CT negative urine specimen with NAAT1 and NAAT2 while they had a CT positive vaginal swab with NAAT1 and NAAT2.

* One subject had unknown symptom status and is not presented in this table.

Note: In the scenario where one or more of the sample types are invalid/not available, for female subjects, the remaining sample types with valid results from NAAT1 and NAAT2 must have concordant positive or concordant negative results to determine the IS as Infected or Non-Infected, respectively. For all other cases where one or more of the sample types are invalid/not available, the IS is indeterminate.

Note: If at least 2 out of the 3 test results, for male subjects, are concordant positive or negative then the IS can be considered as infected or non-infected, respectively. If one test result is invalid/not available and the other two test results are discordant then the IS is indeterminate. If 2 or 3 test results are invalid/not available, then the IS is indeterminate.

Note: Subjects with designated patient infection status (Infected or Non-Infected) and final valid cobas® CT/NG test results are considered evaluable and included in this summary table. An evaluable subject may not have all available sample types or valid test results.

Note: CI = confidence interval, PREV = prevalence, SENS = sensitivity, SPEC = specificity, PPV = positive predictive value,

NPV = negative predictive value.

Note: The predictive values shown above reflect performance specific to the clinical study population and may not be applicable to all individuals in the intended use population.

The overall point estimate of cobas® CT/NG sensitivity for CT detection was 95.1% with a 95% CI of 90.2% to 97.6% for anorectal specimens and 100.0% with a 95% CI of 87.9% to 100% for oropharyngeal specimens. The sensitivity estimates were similar between asymptomatic and symptomatic subjects with overlapping two-sided 95% CIs (Table 32). The overall point estimate of cobas® CT/NG specificity for CT was 99.2% with a 95% CI of 98.8% to 99.5% for anorectal specimens and 99.8% with a 95% CI of 99.6% to 99.9% for oropharyngeal specimens. The specificity estimates were similar between asymptomatic and symptomatic subjects with overlapping two-sided 95% CIs (Table 32).

Table 32 *Chlamydia trachomatis*: overall clinical performance compared with Infection Status (IS) by sample type and symptom status

Sample Type ^a	Symptom Status ^b	Total (N)	SENS	95% Score CI	SPEC	95% Score CI	PREV (%)	PPV	NPV
AR	Symp	741	96.4% (53/55)	(87.7%, 99.0%)	99.0% (679/686)	(97.9%, 99.5%)	7.4	88.3% (53/60)	99.7% (679/681)
AR	Asymp	1,577	94.3% (83/88)	(87.4%, 97.5%)	99.3% (1479/1489)	(98.8%, 99.6%)	5.6	89.2% (83/93)	99.7% (1479/1484)
AR	Unknown	17	NE	NE	100.0% (17/17)	(81.6%, 100.0%)	0.0	NE	100.0% (17/17)
AR	Overall	2,335	95.1% (136/143)	(90.2%, 97.6%)	99.2% (2175/2192)	(98.8%, 99.5%)	6.1	88.9% (136/153)	99.7% (2175/2182)
OP	Symp	744	100.0% (9/9)	(70.1%, 100.0%)	99.7% (733/735)	(99.0%, 99.9%)	1.2	81.8% (9/11)	100.0% (733/733)
OP	Asymp	1,584	100.0% (19/19)	(83.2%, 100.0%)	99.9% (1563/1565)	(99.5%, 100.0%)	1.2	90.5% (19/21)	100.0% (1563/1563)
OP	Unknown	17	NE	NE	100.0% (17/17)	(81.6%, 100.0%)	0.0	NE	100.0% (17/17)
OP	Overall	2,345	100.0% (28/28)	(87.9%, 100.0%)	99.8% (2313/2317)	(99.6%, 99.9%)	1.2	87.5% (28/32)	100.0% (2313/2313)

^aAR = anorectal, OP = oropharyngeal; ^bSymp = symptomatic, Asymp = asymptomatic.

Note: CI = confidence interval, PREV = prevalence; SENS = sensitivity; SPEC = specificity; PPV = positive predictive value;

NPV = negative predictive value; NE = non-estimable.

Note: The predictive values shown above reflect performance specific to the clinical study population and may not be applicable to all individuals in the intended use population.

***Neisseria gonorrhoeae*: Urogenital specimens Infection Status summary**

Table 33 and Table 34 summarize the results from symptomatic and asymptomatic subjects designated as infected or non-infected with NG (females and males, respectively) according to the IS algorithm. A total of 57 females and 87 males were infected with NG. Symptoms were reported in 45.6% (26/57) of infected and 37.2% (1416/3803) of non-infected females. Symptoms were reported in 94.3% (82/87) of infected and 20.2% (223/1105) of non-infected males.

Table 33 NG positive/negative analysis for female Infection Status (IS) (prospective specimens)

Infection Status	NAAT1 UR	NAAT1 VS	NAAT2 UR	NAAT2 VS	cobas® CT/NG UR	cobas® CT/NG VS	cobas® CT/NG PC	cobas® CT/NG ES	SS ^a Symp ^c	SS ^a Asymp ^c	Total
Infected	+	+	+	+	+	+	+	+	20	23	43
Infected	-	+	-	+	-	+	+	+	2	3	5
Infected	+	+	-	+	+	+	+	+	0	2	2
Infected	-	+	-	+	+	+	+	+	2	0	2
Infected	+	+	+	+	+	+	+	Failed	1	0	1
Infected	+	+	+	+	+	+	-	-	0	1	1
Infected	+	+	-	+	-	+	-	-	0	1	1
Infected	-	+	NA	+	+	+	+	-	0	1	1
Infected ^b	+	-	+	-	+	-	-	-	1	0	1
Total									26	31	57
Non-Infected	-	-	-	-	-	-	-	-	1368	2315	3683
Non-Infected	-	+	-	-	-	-	-	-	4	11	15
Non-Infected	+	-	-	-	-	-	-	-	5	7	12
Non-Infected	-	-	NA	-	-	-	-	-	2	7	9
Non-Infected	-	Invalid	-	-	-	-	-	-	5	4	9
Non-Infected	-	-	-	-	-	Invalid	-	-	5	3	8
Non-Infected	-	-	-	-	-	-	-	NA	3	5	8
Non-Infected	-	-	Invalid	-	-	-	-	-	0	8	8
Non-Infected	-	-	-	-	-	+	-	-	2	4	6
Non-Infected	-	-	-	-	-	NA	-	-	1	3	4
Non-Infected	-	NA	-	-	-	-	-	-	0	4	4
Non-Infected	-	-	-	-	-	-	NA	NA	0	3	3
Non-Infected	-	-	-	NA	-	-	-	-	1	2	3
Non-Infected	NA	-	-	-	-	-	-	-	0	3	3
Non-Infected	Invalid	-	-	-	-	-	-	-	2	1	3
Non-Infected	+	+	-	-	-	+	-	-	0	2	2
Non-Infected	-	-	-	-	+	-	-	-	2	0	2
Non-Infected	-	-	-	-	-	-	-	Invalid	2	0	2
Non-Infected	+	+	-	-	-	-	-	-	0	1	1
Non-Infected	+	+	-	-	-	Invalid	-	-	1	0	1
Non-Infected	-	+	-	-	-	+	+	-	1	0	1
Non-Infected	-	+	-	-	-	+	-	-	1	0	1
Non-Infected	-	-	+	+	+	-	-	-	1	0	1
Non-Infected	-	-	-	+	-	+	-	-	0	1	1
Non-Infected	-	-	-	-	-	-	+	+	0	1	1

Infection Status	NAAT1 UR	NAAT1 VS	NAAT2 UR	NAAT2 VS	cobas® CT/NG UR	cobas® CT/NG VS	cobas® CT/NG PC	cobas® CT/NG ES	SS ^a Symp ^c	SS ^a Asymp ^c	Total
Non-Infected	-	-	-	-	-	-	-	+	1	0	1
Non-Infected	-	-	-	-	-	Failed	-	-	1	0	1
Non-Infected	-	-	-	-	Failed	-	-	-	1	0	1
Non-Infected	-	-	-	-	-	-	-	Failed	1	0	1
Non-Infected	-	-	-	-	-	-	NA	-	0	1	1
Non-Infected	-	-	-	-	-	-	Invalid	-	1	0	1
Non-Infected	-	-	-	-	-	NA	Invalid	-	1	0	1
Non-Infected	-	-	-	-	-	-	Invalid	Invalid	1	0	1
Non-Infected	-	-	-	-	-	Invalid	Invalid	Invalid	1	0	1
Non-Infected	-	-	-	-	-	-	Failed	-	0	1	1
Non-Infected	-	-	-	Invalid	-	-	-	-	1	0	1
Non-Infected	-	Invalid	-	-	-	Invalid	-	-	1	0	1
Total									1416	2387	3803

^aSS=symptom status

^cSymp = symptomatic, Asymp = asymptomatic.

^b Infected (Urine), Non-Infected (Swabs).

Note: In the scenario where one or more of the sample types are invalid/not available (NA), for female subjects, the remaining sample types with valid results from NAAT1 and NAAT2 must have concordant positive or concordant negative results to determine the IS as Infected or Not Infected, respectively. For all other cases where one or more of the sample types are invalid/not available (NA), the IS is indeterminate.

Note: Female subjects with designated infection status (Infected or Non-Infected) and final valid cobas® CT/NG test results are considered evaluable and included in this summary table.

Note: + denotes Positive, - denotes Negative, NA denotes Not Available.

Note: UR = urine, VS = vaginal swab, PC = PreservCyt®, ES = endocervical swab.

Note: cobas® Invalid are the sum of instrument amplification/detection errors and samples excluded due to protocol deviations.

Note: cobas® Failed are hardware, software or operator errors causing no result reported.

Table 34 NG positive/negative analysis for male Infection Status (IS)

Infection Status	NAAT1 UR	NAAT2 UR	NAAT3 UR	cobas® CT/NG UR	Symptom Status Symp ^a	Symptom Status Asymp ^a	Total
Infected	+	+	+	+	81	5	86
Infected	NA	+	+	+	1	0	1
Total Infected					82	5	87
Non-Infected	-	-	-	-	215	863	1078
Non-Infected	+	-	-	-	2	7	9
Non-Infected	-	Invalid	-	-	3	2	5
Non-Infected	-	-	-	+	2	2	4
Non-Infected	Invalid	-	-	-	0	3	3
Non-Infected	-	-	Invalid	-	0	3	3

Infection Status	NAAT1 UR	NAAT2 UR	NAAT3 UR	cobas® CT/NG UR	Symptom Status Symp ^a	Symptom Status Asymp ^a	Total
Non-Infected	-	+	-	+	1	1	2
Non-Infected	NA	-	-	-	0	1	1
Total Non-Infected					223	882	1105*

Symp = symptomatic, Asymp = asymptomatic.

*One subject had unknown symptom status and is not included in this table.

Note: If at least 2 out of the 3 test results, for male subjects, are concordant positive or negative then the IS can be considered as Infected or Non-Infected, respectively. If one test result is invalid/not available (NA) and the other two test results are discordant then the IS is indeterminate. If 2 or 3 test results are invalid/not available, then the IS is indeterminate.

Note: Male subjects with designated patient infection status (Infected or Non-Infected) and final valid cobas® CT/NG test results are considered evaluable and included in this summary table.

Note: cobas® Invalid are the sum of instrument amplification/detection errors and samples excluded due to protocol deviations

Note: + denotes Positive, - denotes Negative, NA denotes Not Available.

Note: UR = urine.

***Neisseria gonorrhoeae*: Extragenital specimens Infection Status summary**

Table 35 summarizes the results from evaluable subjects designated as NG positive or negative according to the IS algorithm for both Anorectal (AR) and Oropharyngeal (OP) specimens. Of the 2,365 contributing subjects for Rectum, 15 subjects had NG uninterpretable IS, 12 were excluded due to protocol deviations and the remaining 2,338 were evaluable. Similarly, of the 2,382 contributing subjects for Oropharyngeal, 19 subjects had NG uninterpretable IS, 11 were excluded due to protocol deviations, 3 were excluded due to failed test results and the remaining 2,349 were evaluable.

Table 35 *Neisseria gonorrhoeae*: Summary of Infection Status interpretation for anorectal and oropharyngeal specimen types

Specimen Type ^a	NAAT A	NAAT B	NAAT C	IS ^b Interpretation	cobas® CT/NG	SS ^d Symp ^c	SS ^d Asymp ^c	SS ^d Unkn ^c	Total
AR	Inv	+	+	Positive	+	2	0	0	2
AR	-	+	+	Positive	-	1	0	0	1
AR	-	+	+	Positive	+	3	4	0	7
AR	+	NA	+	Positive	+	0	1	0	1
AR	+	Inv	+	Positive	+	0	1	0	1
AR	+	-	+	Positive	+	0	1	0	1
AR	+	+	+	Positive	+	37	50	1	88
AR				Total Positive		43	57	1	101
AR	Inv	-	-	Negative	-	27	50	1	78
AR	Inv	-	-	Negative	+	1	0	0	1
AR	-	NA	-	Negative	-	7	2	3	12
AR	-	Inv	-	Negative	-	3	2	0	5
AR	-	-	-	Negative	-	646	1,461	12	2,119
AR	-	-	-	Negative	+	3	3	0	6

Specimen Type ^a	NAAT A	NAAT B	NAAT C	IS ^b Interpretation	cobas® CT/NG	SS ^d Symp ^c	SS ^d Asymp ^c	SS ^d Unkn ^c	Total
AR	-	-	+	Negative	-	5	0	0	5
AR	-	-	+	Negative	+	6	1	0	7
AR	-	+	-	Negative	-	0	2	0	2
AR	+	-	-	Negative	-	0	1	0	1
AR	+	-	-	Negative	+	1	0	0	1
AR				Total Negative		699	1,522	16	2,237
OP	Inv	+	+	Positive	+	1	1	0	2
OP	-	+	+	Positive	+	9	8	0	17
OP	+	NA	+	Positive	+	0	1	0	1
OP	+	Inv	+	Positive	+	0	1	0	1
OP	+	-	+	Positive	+	1	2	0	3
OP	+	+	-	Positive	+	0	1	0	1
OP	+	+	+	Positive	+	41	30	0	71
OP				Total Positive		52	44	0	96
OP	Inv	-	-	Negative	-	30	53	1	84
OP	-	NA	-	Negative	-	5	6	2	13
OP	-	Inv	-	Negative	-	0	5	0	5
OP	-	-	Inv	Negative	-	2	0	0	2
OP	-	-	Inv	Negative	+	1	0	0	1
OP	-	-	-	Negative	-	631	1,452	13	2,096
OP	-	-	-	Negative	+	6	7	1	14
OP	-	-	+	Negative	-	4	3	0	7
OP	-	-	+	Negative	+	4	4	0	8
OP	-	+	-	Negative	-	5	15	0	20
OP	-	+	-	Negative	+	0	1	0	1
OP	+	-	-	Negative	-	1	0	0	1
OP	+	-	-	Negative	+	0	1	0	1
OP				Total Negative		689	1,547	17	2,253

^a AR = anorectal; OP = oropharyngeal.

^b IS= infection status

^cSymp = symptomatic, Asymp = asymptomatic, Unkn = Unknown symptom status.

^dSS=symptom status

Note: NA = Not available, Inv = Invalid.

Note: Infection status (IS) is determined for each specimen type. The IS of a sample will be established by the concordance results from at least 2 out of 3 comparator assays (NAAT A, NAAT B, NAAT C).

If one of the comparator assays is Uninterpretable/Invalid/Failed, the two remaining assays must be concordant to define the IS as Positive (+) or Negative (-).

Note: Of the 2,365 contributing subjects for Rectum, 15 subjects had NG uninterpretable IS. Similarly, of the 2,382 contributing subjects for Oropharyngeal, 19 subjects had NG uninterpretable IS.

Note: Any IS interpretation that is Uninterpretable/Invalid/Failed/Protocol deviations are excluded from performance analyses.

Neisseria gonorrhoeae: performance results

Sensitivity, specificity, and predictive values of cobas® CT/NG for NG as defined by IS are presented by gender, sample type, and symptom status in Table 36 (prospective and archived prospectively collected specimens) for urogenital specimens and in Table 37 for extra-genital specimens.

Table 36 NG clinical performance compared with Infection Status (IS) by gender, sample type, and symptom status (prospective and archived prospectively collected specimens)

Sample Type ^a	Gender	Symptom Status ^b	Total (n)	SENS	95% Score CI	SPEC	95% Score CI	PREV (%)	PPV (%)	NPV (%)
UR (prospective)	Female	Symp	1441	92.3% (24/26)	(75.9%, 97.9%)	99.8% (1412/1415)	(99.4%, 99.9%)	1.8	88.9	99.9
UR (prospective)	Female	Asymp	2418	87.1% (27/31)	(71.1%, 94.9%)	100.0% (2387/2387)	(99.8%, 100.0%)	1.3	100.0	99.8
UR (prospective)	Female	Overall	3859	89.5% (51/57) ^c	(78.9%, 95.1%)	99.9% (3799/3802)	(99.8%, 100.0%)	1.5	94.4	99.8
UR (archived)	Female	Symp	94	100.0% (35/35)	(90.1%, 100.0%)	100.0% (59/59)	(93.9%, 100.0%)	37.2	100.0	100.0
UR (archived)	Female	Asymp	101	97.6% (41/42)	(87.7%, 99.6%)	100.0% (59/59)	(93.9%, 100.0%)	41.6	100.0	98.3
UR (archived)	Female	Overall	195	98.7% (76/77)	(93.0%, 99.8%)	100.0% (118/118)	(96.8%, 100.0%)	39.5	100.0	99.2
UR (prospective and archived)	Female	Symp	1535	96.7% (59/61)	(88.8%, 99.1%)	99.8% (1471/1474)	(99.4%, 99.9%)	4.0	95.2	99.9
UR (prospective and archived)	Female	Asymp	2519	93.2% (68/73)	(84.9%, 97.0%)	100.0% (2446/2446)	(99.8%, 100.0%)	2.9	100.0	99.8
UR (prospective and archived)	Female	Overall	4054	94.8% (127/134)	(89.6%, 97.4%)	99.9% (3917/3920)	(99.8%, 100.0%)	3.3	97.7	99.8
VS-C	Female	Symp	711	100.0% (11/11)	(74.1%, 100.0%)	99.7% (698/700)	(99.0%, 99.9%)	1.5	84.6	100.0
VS-C	Female	Asymp	1225	100.0% (17/17)	(81.6%, 100.0%)	99.8% (1205/1208)	(99.3%, 99.9%)	1.4	85.0	100.0
VS-C	Female	Overall	1936	100.0% (28/28)	(87.9%, 100.0%)	99.7% (1903/1908)	(99.4%, 99.9%)	1.4	84.8	100.0
VS-S	Female	Symp	720	100.0% (14/14)	(78.5%, 100.0%)	99.7% (704/706)	(99.0%, 99.9%)	1.9	87.5	100.0
VS-S	Female	Asymp	1187	100.0% (14/14)	(78.5%, 100.0%)	99.7% (1169/1173)	(99.1%, 99.9%)	1.2	77.8	100.0
VS-S	Female	Overall	1907	100.0% (28/28)	(87.9%, 100.0%)	99.7% (1873/1879)	(99.3%, 99.9%)	1.5	82.4	100.0
PC (prospective)	Female	Symp	1438	100.0% (25/25)	(86.7%, 100.0%)	99.9% (1412/1413)	(99.6%, 100.0%)	1.7	96.2	100.0
PC (prospective)	Female	Asymp	2413	93.5% (29/31)	(79.3%, 98.2%)	100.0% (2381/2382)	(99.8%, 100.0%)	1.3	96.7	99.9
PC (prospective)	Female	Overall	3851	96.4% (54/56)	(87.9%, 99.0%)	99.9% (3793/3795)	(99.8%, 100.0%)	1.5	96.4	99.9
PC (archived)	Female	Symp	48	95.7% (22/23)	(79.0%, 99.2%)	100.0% (25/25)	(86.7%, 100.0%)	47.9	100.0	96.2

Sample Type ^a	Gender	Symptom Status ^b	Total (n)	SENS	95% Score CI	SPEC	95% Score CI	PREV (%)	PPV (%)	NPV (%)
PC (archived)	Female	Asymp	23	100.0% (10/10)	(72.2%, 100.0%)	100.0% (13/13)	(77.2%, 100.0%)	43.5	100.0	100.0
PC (archived)	Female	Overall	71	97.0% (32/33)	(84.7%, 99.5%)	100.0% (38/38)	(90.8%, 100.0%)	46.5	100.0	97.4
PC (prospective and archived)	Female	Symp	1486	97.9% (47/48)	(89.1%, 99.6%)	99.9% (1437/1438)	(99.6%, 100.0%)	3.2	97.9	99.9
PC (prospective and archived)	Female	Asymp	2436	95.1% (39/41)	(83.9%, 98.7%)	100.0% (2394/2395)	(99.8%, 100.0%)	1.7	97.5	99.9
PC (prospective and archived)	Female	Overall	3922	96.6% (86/89)	(90.6%, 98.8%)	99.9% (3831/3833)	(99.8%, 100.0%)	2.3	97.7	99.9
ES (prospective)	Female	Symp	1433	100.0% (24/24)	(86.2%, 100.0%)	99.9% (1408/1409)	(99.6%, 100.0%)	1.7	96.0	100.0
ES (prospective)	Female	Asymp	2410	90.3% (28/31)	(75.1%, 96.7%)	100.0% (2378/2379)	(99.8%, 100.0%)	1.3	96.6	99.9
ES (prospective)	Female	Overall	3843	94.5% (52/55)	(85.1%, 98.1%)	99.9% (3786/3788)	(99.8%, 100.0%)	1.4	96.3	99.9
ES (archived)	Female	Symp	51	100.0% (21/21)	(84.5%, 100.0%)	100.0% (30/30)	(88.6%, 100.0%)	41.2	100.0	100.0
ES (archived)	Female	Asymp	54	100.0% (24/24)	(86.2%, 100.0%)	100.0% (30/30)	(88.6%, 100.0%)	44.4	100.0	100.0
ES (archived)	Female	Overall	105	100.0% (45/45)	(92.1%, 100.0%)	100.0% (60/60)	(94.0%, 100.0%)	42.9	100.0	100.0
ES (prospective and archived)	Female	Symp	1484	100.0% (45/45)	(92.1%, 100.0%)	99.9% (1438/1439)	(99.6%, 100.0%)	3.0	97.8	100.0
ES (prospective and archived)	Female	Asymp	2464	94.5% (52/55)	(85.1%, 98.1%)	100.0% (2408/2409)	(99.8%, 100.0%)	2.2	98.1	99.9
ES (prospective and archived)	Female	Overall	3948	97.0% (97/100)	(91.5%, 99.0%)	99.9% (3846/3848)	(99.8%, 100.0%)	2.5	98.0	99.9
UR	Male	Symp	305	100.0% (82/82)	(95.5%, 100.0%)	98.7% (220/223)	(96.1%, 99.5%)	26.9	96.5	100.0
UR	Male	Asymp	887	100.0% (5/5)	(56.6%, 100.0%)	99.7% (879/882)	(99.0%, 99.9%)	0.6	62.5	100.0
UR	Male	Overall	1192*	100.0% (87/87)	(95.8%, 100.0%)	99.5% (1099/1105)	(98.8%, 99.8%)	7.3	93.5	100.0

^a UR = urine, VS-C = clinician-collected vaginal swab, VS-S = self-collected vaginal swab, PC = PreservCyt®, ES = endocervical swab.

^b Symp = symptomatic, Asymp = asymptomatic.

^c Five NG IS infected females had a NG negative urine specimen with NAAT1 and NAAT2 while they had a NG positive vaginal swab with NAAT1 and NAAT2.

* One subject had unknown symptom status and is not included in this table.

Note: In the scenario where one or more of the sample types are invalid/not available, for female subjects, the remaining sample types with valid results from NAAT1 and NAAT2 must have concordant positive or concordant negative results to determine the IS as Infected or Non-Infected, respectively. For all other cases where one or more of the sample types are invalid/ not available, the IS is indeterminate.

Note: If at least 2 out of the 3 test results, for male subjects, are concordant positive or negative then the IS can be considered as Infected or Non-

Infected, respectively. If one test result is invalid/not available and the other two test results are discordant then the IS is indeterminate. If 2 or 3 test results are invalid/not available, then the IS is indeterminate.

Note: Subjects with designated patient infection status (Infected or Non-Infected) and final valid **cobas**® CT/NG test results are considered evaluable and included in this summary table. An evaluable subject may not have all available sample types or valid test results.

Note: Archived prospectively collected specimens were from COB-CTNG-282 study and included female IS positive subjects that have available sample with adequate volume for testing.

Note: CI = confidence interval, PREV = prevalence, SENS = sensitivity, SPEC = specificity, PPV = positive predictive value,

NPV = negative predictive value.

Note: The predictive values shown above reflect performance specific to the clinical study population and may not be applicable to all individuals in the intended use population.

Table 37 *Neisseria gonorrhoeae*: overall clinical performance compared with infection status by sample type and symptom status

Sample Type ^a	Symptom Status ^b	Total (N)	SENS	95% Score CI	SPEC	95% Score CI	PREV (%)	PPV	NPV
AR	Symp	742	97.7% (42/43)	(87.9%, 99.6%)	98.4% (688/699)	(97.2%, 99.1%)	5.8	79.2% (42/53)	99.9% (688/689)
AR	Asymp	1,579	100.0% (57/57)	(93.7%, 100.0%)	99.7% (1518/1522)	(99.3%, 99.9%)	3.6	93.4% (57/61)	100.0% (1518/1518)
AR	Unknown	17	100.0% (1/1)	(20.7%, 100.0%)	100.0% (16/16)	(80.6%, 100.0%)	5.9	100.0% (1/1)	100.0% (16/16)
AR	Overall	2,338	99.0% (100/101)	(94.6%, 99.8%)	99.3% (2222/2237)	(98.9%, 99.6%)	4.3	87.0% (100/115)	100.0% (2222/2223)
OP	Symp	741	100.0% (52/52)	(93.1%, 100.0%)	98.4% (678/689)	(97.2%, 99.1%)	7.0	82.5% (52/63)	100.0% (678/678)
OP	Asymp	1,591	100.0% (44/44)	(92.0%, 100.0%)	99.2% (1534/1547)	(98.6%, 99.5%)	2.8	77.2% (44/57)	100.0% (1534/1534)
OP	Unknown	17	NE	NE	94.1% (16/17)	(73.0%, 99.0%)	0.0	0.0% (0/1)	100.0% (16/16)
OP	Overall	2,349	100.0% (96/96)	(96.2%, 100.0%)	98.9% (2228/2253)	(98.4%, 99.2%)	4.1	79.3% (96/121)	100.0% (2228/2228)

^a AR = anorectal; OP = oropharyngeal.

^b Symp = symptomatic, Asymp = asymptomatic

Note: CI = confidence interval, PREV = prevalence, SENS = sensitivity, SPEC = specificity, PPV = positive predictive value, NPV = negative predictive value, NE = non-estimable.

Note: The predictive values shown above reflect performance specific to the clinical study population and may not be applicable to all individuals in the intended use population.

Expected values for urogenital specimens

Prevalence

The prevalence of CT and NG in patient populations depends on a variety of factors including age, gender, the presence of symptoms, clinic type, and test method. The positivity rate of CT observed with **cobas**® CT/NG during this multi-site clinical study was 7.2% overall. The overall positivity rate of NG observed with **cobas**® CT/NG for the prospective and archived prospectively collected samples was 2.7%.

Positive and negative predictive values for hypothetical prevalence rates

The positive and negative predictive values of all in vitro diagnostic tests are highly dependent on prevalence. The **cobas**® CT/NG performance may vary depending on the prevalence and the population tested. Hypothetical positive and negative values (PPV and NPV) derived from disease prevalence of 1 to 50% for **cobas**® CT/NG are shown in Table 38 and Table 39. These tables use the overall sensitivity and specificity (compared with IS) across all urogenital sample types in both female and male subjects: 95.5% and 99.5% respectively for CT, and 96.5% and 99.9% respectively for NG.

Table 38 Positive and negative predictive values for hypothetical CT prevalence

Prevalence (%)	Sensitivity ^a (%)	Specificity ^a (%)	PPV (%)	NPV (%)
1	95.5	99.5	63.89	99.95
3	95.5	99.5	84.41	99.86
5	95.5	99.5	90.21	99.77
10	95.5	99.5	95.11	99.51
15	95.5	99.5	96.87	99.22
20	95.5	99.5	97.77	98.89
30	95.5	99.5	98.69	98.12
50	95.5	99.5	99.43	95.72

Note: PPV = Positive predictive value, NPV = Negative predictive value.

^aThe overall sensitivity and specificity were estimated by comparing the **cobas**® CT/NG Test results to Infection Status across all sample types in both female and male subjects.

Table 39 Positive and negative predictive values for hypothetical NG prevalence

Prevalence (%)	Sensitivity ^a (%)	Specificity ^a (%)	PPV (%)	NPV (%)
1	96.5	99.9	86.86	99.96
3	96.5	99.9	95.29	99.89
5	96.5	99.9	97.18	99.81
10	96.5	99.9	98.64	99.61
15	96.5	99.9	99.14	99.38
20	96.5	99.9	99.39	99.12
30	96.5	99.9	99.64	98.50
50	96.5	99.9	99.85	96.58

Note: PPV = Positive predictive value, NPV = Negative predictive value.

^aThe overall sensitivity and specificity were estimated by comparing the **cobas**® CT/NG test results to Infection Status across all sample types in both female and male subjects.

Expected values for extragenital specimens

Prevalence

Positive and negative predictive values for hypothetical prevalence rates

The hypothetical PPVs and NPVs of cobas® CT/NG derived from CT disease prevalence of 1% to 50% are shown in Table 40 for anorectal specimens and Table 41 for oropharyngeal specimens.

Table 40 Positive Predictive Value and Negative Predictive Value for hypothetical *Chlamydia trachomatis* prevalence for anorectal specimens

Hypothetical Prevalence (%)	Sensitivity (%) ^a	Specificity (%) ^a	PPV (%)	NPV (%)
1	95.1	99.2	55.33	99.95
3	95.1	99.2	79.14	99.85
5	95.1	99.2	86.59	99.74
10	95.1	99.2	93.16	99.45
15	95.1	99.2	95.58	99.14
20	95.1	99.2	96.84	98.78
30	95.1	99.2	98.13	97.93
50	95.1	99.2	99.19	95.30

^a The overall sensitivity and specificity were estimated by comparing the test results with cobas® CT/NG to the Infection Status across all genders for CT anorectal.

Note: PPV = Positive predictive value, NPV = Negative predictive value.

Table 41 Positive Predictive Value and Negative Predictive Value for hypothetical *Chlamydia trachomatis* prevalence for oropharyngeal specimens

Hypothetical Prevalence (%)	Sensitivity (%) ^a	Specificity (%) ^a	PPV (%)	NPV (%)
1	100.0	99.8	85.41	100.0
3	100.0	99.8	94.71	100.0
5	100.0	99.8	96.82	100.0
10	100.0	99.8	98.47	100.0
15	100.0	99.8	99.03	100.0
20	100.0	99.8	99.31	100.0
30	100.0	99.8	99.60	100.0
50	100.0	99.8	99.83	100.0

^a The overall sensitivity and specificity were estimated by comparing the test results with cobas® CT/NG to the Infection Status across all genders for CT oropharyngeal.

Note: PPV = Positive predictive value, NPV = Negative predictive value.

Hypothetical PPVs and NPVs of cobas® CT/NG derived from NG disease prevalence of 1% to 50% are shown in Table 42 for anorectal specimens and Table 43 for oropharyngeal specimens.

Table 42 Positive Predictive Value and Negative Predictive Value for Hypothetical *Neisseria gonorrhoeae* prevalence for anorectal specimens

Hypothetical Prevalence (%)	Sensitivity (%) ^a	Specificity (%) ^a	PPV (%)	NPV (%)
1	99.0	99.3	59.86	99.99
3	99.0	99.3	82.04	99.97
5	99.0	99.3	88.60	99.95
10	99.0	99.3	94.26	99.89
15	99.0	99.3	96.30	99.82
20	99.0	99.3	97.36	99.75
30	99.0	99.3	98.44	99.57
50	99.0	99.3	99.33	99.01

^a The overall sensitivity and specificity were estimated by comparing the test results with cobas® CT/NG to the Infection Status across all genders for NG Anorectal.

Note: PPV = Positive predictive value, NPV = Negative predictive value.

Table 43 Positive Predictive Value and Negative Predictive Value for Hypothetical *Neisseria gonorrhoeae* prevalence for oropharyngeal specimens

Hypothetical Prevalence (%)	Sensitivity (%) ^a	Specificity (%) ^a	PPV (%)	NPV (%)
1	100.0	98.9	47.65	100.0
3	100.0	98.9	73.60	100.0
5	100.0	98.9	82.59	100.0
10	100.0	98.9	90.92	100.0
15	100.0	98.9	94.08	100.0
20	100.0	98.9	95.75	100.0
30	100.0	98.9	97.48	100.0
50	100.0	98.9	98.90	100.0

^a The overall sensitivity and specificity were estimated by comparing the test results with cobas® CT/NG to the Infection Status across all genders for NG oropharyngeal.

Note: PPV = Positive predictive value, NPV = Negative predictive value.

Table 44 and Table 45 present the positivity rate as determined by the cobas® CT/NG test for *C. trachomatis* and *N. gonorrhoeae* respectively. Overall, the observed positivity rate for *C. trachomatis* during the clinical study, when testing with the cobas® CT/NG test, was 1.4% and 6.6% for oropharyngeal and anorectal swabs, respectively; similarly, the observed positivity rate for *N. gonorrhoeae*, as determined by the cobas® CT/NG test, was 5.2% and 4.9% for oropharyngeal and anorectal swabs, respectively. The positivity rate for each site and overall is shown below.

Table 44 CT Positivity rate as determined by **cobas** CT/NG for oropharyngeal and anorectal specimen types

Collection Site ID	OP ^a Number of Samples Tested with cobas valid results (N)	OP ^a Number of Positive Results by cobas CT/NG (n)	OP ^a Positivity Rate (%) ^c (n/N)	AR ^b Number of Samples Tested (N)	AR ^b Number of Positive Results by cobas CT/NG (n)	AR ^b Positivity Rate (%) ^c (n/N)
10	170	2	1.2%	170	6	3.5%
11	90	1	1.1%	89	4	4.5%
12	388	6	1.5%	385	49	12.7%
13	171	1	0.6%	170	3	1.8%
14	259	2	0.8%	256	18	7.0%
15	433	10	2.3%	426	36	8.5%
16	394	6	1.5%	395	19	4.8%
17	457	5	1.1%	456	21	4.6%
Total	2362	33	1.4%	2347	156	6.6%

^a OP= Oropharyngeal / Throat specimen type.^b AR= Anorectal specimen type.^c Positivity Rate (%) = (Number of valid Positive **cobas** results/Total number of **cobas** valid results) x100.**Table 45** NG positivity rate as determined by **cobas**® CT/NG for oropharyngeal and anorectal specimen types


Collection Site ID	OP ^a Number of Samples Tested with cobas valid results (N)	OP ^a Number of Positive Results by cobas CT/NG (n)	OP ^a Positivity Rate (%) ^c (n/N)	AR ^b Number of Samples Tested (N)	AR ^b Number of Positive Results by cobas CT/NG (n)	AR ^b Positivity Rate (%) ^c (n/N)
10	170	6	3.5%	170	4	2.4%
11	90	7	7.8%	89	4	4.5%
12	388	51	13.1%	385	48	12.5%
13	171	0	0 %	170	3	1.8%
14	259	21	8.1%	256	18	7.0%
15	433	14	3.2%	426	15	3.5%
16	394	10	2.5%	395	8	2.0%
17	457	14	3.1%	456	15	3.3%
Total	2362	123	5.2%	2347	115	4.9%

^a OP= Oropharyngeal/Throat specimen type.^b AR= Anorectal / Rectum specimen type.^c Positivity Rate (%) = (Number of valid Positive **cobas** results/Total number of **cobas** valid results) x100.

Cycle threshold frequency distribution


The frequency distribution of cobas® CT/NG positive results for CT and NG infected specimens are shown in Figure 5 and Figure 6, respectively for urogenital specimens.

Figure 5 Cycle threshold distribution of CT positive specimens-urogenital specimens



Ct = cycle threshold value; CT = *Chlamydia trachomatis*.


Figure 6 Cycle threshold distribution of NG positive specimens-urogenital specimens



Ct = cycle threshold value; NG = *Neisseria gonorrhoeae*


For extragenital specimens, the frequency distribution of cobas® CT/NG–positive results for CT anorectal, CT oropharyngeal, NG anorectal, and NG oropharyngeal are shown in Figure 7, Figure 8, Figure 9, and Figure 10, respectively.

Figure 7 Distribution of cycle threshold values for cobas® CT/NG (*Chlamydia trachomatis* anorectal specimens)




Ct = cycle threshold; CT = *Chlamydia trachomatis*.

Figure 8 Distribution of cycle threshold values for cobas® CT/NG (*Chlamydia trachomatis* oropharyngeal specimens)




Ct = cycle threshold; CT = *Chlamydia trachomatis*.

Figure 9 Distribution of cycle threshold values for **cobas[®] CT/NG** (*Neisseria gonorrhoeae* anorectal specimens)



Ct = cycle threshold; NG = *Neisseria gonorrhoeae*.

Figure 10 Distribution of cycle threshold values for **cobas[®] CT/NG** (*Neisseria gonorrhoeae* oropharyngeal specimens)



Ct = cycle threshold; NG = *Neisseria gonorrhoeae*.

Additional information

Key assay features

Sample types

- Endocervical swab collected in **cobas**® PCR Media
- Vaginal swab collected in **cobas**® PCR Media
- Self-collected Vaginal swab collected in **cobas**® PCR Media
- Oropharyngeal swab collected in **cobas**® PCR Media
- Anorectal swab collected in **cobas**® PCR Media
- Male and female urine stabilized in **cobas**® PCR Media
- Cervical specimen collected in PreservCyt® Solution

**Amount of sample
required/processed**

- ≥1000 µL required in sample tube for all swab samples, instrument processes 400 µL
- ≥1000 µL required in sample tube for PreservCyt® samples, instrument processes 400 µL
- ≥1200 µL required in sample tube for urine samples, instrument processes 850 µL



Test duration

- < 3.5 hours to first result

Symbols

The following symbols are used in labeling for Roche PCR diagnostic products.

Table 46 Symbols used in labeling for Roche PCR diagnostics products

 Age or Date of Birth	 Device not for near-patient testing	 QS IU per PCR reaction, use the QS International Units (IU) per PCR reaction in calculation of the results.
 Ancillary Software	 Device not for self-testing	
 Assigned Range [copies/mL] Assigned Range (copies/mL)	 Distributor (Note: The applicable country/region may be designated beneath the symbol)	 Serial number
 Assigned Range [IU/mL] Assigned Range (IU/mL)	 Do not re-use	 Site
 Authorized representative in the European Community	 Female	 Standard Procedure
 Barcode Data Sheet	 For IVD performance evaluation only	 Sterilized using ethylene oxide
 Batch code	 Global Trade Item Number	 Store in dark
 Biological risks	 Importer	 Temperature limit
 Catalogue number	 In vitro diagnostic medical device	 Test Definition File
 CE marking of conformity; this device is in conformity with the applicable requirements for CE marking of an in vitro diagnostic medical device	 Lower Limit of Assigned Range	 This way up
 Collect date	 Male	 Ultrasensitive Procedure
 Consult instructions for use	 Manufacturer	 Unique Device Identifier
 Contains sufficient for <n> tests	 Negative control	 Upper Limit of Assigned Range
 Content of kit	 Non-sterile	 Urine Fill Line
 Control	 Patient Name	 US Only: Federal law restricts this device to sale by or on the order of a physician.
 Date of manufacture	 Patient number	 Use-by date
 Device for near-patient testing	 Peel here	
 Device for self-testing	 Positive control	
	 QS copies per PCR reaction, use the QS copies per PCR reaction in calculation of the results.	

Technical support

For technical support (assistance) please reach out to your local affiliate: https://www.roche.com/about/business/roche_worldwide.htm

Manufacturer and importer

Table 47 Manufacturer and importer



Roche Molecular Systems, Inc.
1080 US Highway 202 South
Branchburg, NJ 08876 USA
www.roche.com

Made in USA



Roche Diagnostics GmbH
Sandhofer Str. 116
68305 Mannheim
Germany



Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim, Germany

Trademarks and patents

See <https://diagnostics.roche.com/us/en/about-us/patents>

Copyright

©2023 Roche Molecular Systems, Inc.



References

1. Bebear C, de Barbeyrac B. Genital Chlamydia trachomatis infections. *Clinical Microbial Infect.* 2009; 15:4-10.
2. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep.* 2015; 64:1-137.
3. CDC. Sexually Transmitted Disease Surveillance 2013.
4. Haggerty CL, Ness RB. Epidemiology, pathogenesis and treatment of pelvic inflammatory disease. *Expert Rev Anti Infect Ther.* 2006; 4:235-47.
5. Papp JR, Schachter, J, Gaydos CA, Van Der Pol B. Recommendations for the Laboratory-Based Detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* - 2014. *MMWR Recomm Rep.* 2014; 63:1-19.
6. LeFevre ML. Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med.* 2014; 161:902-10.
7. Scholes D, Stergachis A, Heidrich FE, et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. *N Engl J Med.* 1996; 334:1362-1366.
8. Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. *Sex Transm Dis.* 1996; 23:384-91.
9. Gift TL, Blake DR, Gaydos CA, Marrazzo JM. The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature. *Sex Transm Dis.* 2008; 35 (11 Suppl):S51-60.
10. Gift TL, Gaydos CA, Kent CK, et al. The program cost and cost-effectiveness of screening men for Chlamydia to prevent pelvic inflammatory disease in women. *Sex Transm Dis.* 2008; 35 (11 Suppl):S66-75.
11. Satterwhite CL, Torrone E, Meites E, Dunne EF, Mahajan R, Ocfemia MC, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. *Sex Transm Dis.* 2013; 40:187-93.
12. Handsfield HH, Lipman TO, Harnisch JP, Tronca E, Holmes KK. Asymptomatic gonorrhea in men. Diagnosis, natural course, prevalence and significance. *N Engl J Med.* 1974; 290:117-23.
13. McCormack WM, Stumacher RJ, Johnson K, Donner A. Clinical spectrum of gonococcal infection in women. *Lancet.* 1977; 1:1182-5.
14. Ross JD. An update on pelvic inflammatory disease. *Sex Transm Infect.* 2002; 78:18-9.
15. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. *MMWR Recomm Rep.* 2010; 59:1-110.
16. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. *Gene.* 1990; 93:125-8.
17. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. *Biotechnology (NY).* 1992; 10:413-7.
18. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. *Genome Res.* 1996; 6:986-94.

19. Center for Disease Control and Prevention. Biosafety in microbiological and biomedical laboratories, 5th ed. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health HHS Publication No. (CDC) 21-1112, revised December 2009.
20. Clinical and Laboratory Standards Institute (CLSI). Protection of laboratory workers from occupationally acquired infections. Approved Guideline-Fourth Edition. CLSI Document M29-A4:Wayne, PA;CLSI, 2014.
21. International Air Transport Association. Dangerous Goods Regulations, 57th Edition. 2016.
22. Obergfell KP, Seifert H. Mobile DNA in the Pathogenic *Neisseria*. Microbiology Spectrum. 2014; 3:1-18.

Document revision

Document Revision Information	
Doc Rev 7.0 01/2023	Updated Trademarks and patents section, including the link. Added US Clinical Trial Data. Please contact your local Roche Representative if you have any questions.

The summary of safety and performance report can be found using the following link:

<https://ec.europa.eu/tools/eudamed>